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ABSTRACT 
 
ANALYSIS STRATEGIES FOR BIOACTIVE, POLAR FATTY AMIDES IN 
COMPLEX SAMPLES 
 
 
 
By 
Erin Blaine Divito 
December 2013 
 
Dissertation supervised by Michael Cascio 
 Bioactive lipids are known to exert physiological effects and interact with 
neuroreceptors. Little is known about the bioregulation of primary fatty acid amides, 
though N-acyl glycines are thought to be their anabolic precursors. Chapter 1 details the 
current metabolic, physiological, and receptor interactions of primary fatty acid amides 
and their related congeners and reviews current strategies for isolation and detection. 
Chapter 2 outlines mass spectrometry collision induced fragmentation assignments 
pertaining to method development of multiple reaction monitoring detection of these 
species. Chromatographic separation methods of fatty acyls, with a focus on primary fatty 
acid amides and N-acyl glycines, are outlined in chapter 3 and these results are used to 
develop a two dimensional liquid chromatography tandem mass spectrometry analysis 
method. Multiple reaction monitoring was utilized as the detection mode due to the 
 v 
enhanced limit of detection obtained from mass filtering background and matrix 
components. The implementation of our developed analytical separation and detection 
approach for quantitation of these bioactive lipids in vertebrate samples and future 
implications of primary fatty acid amide and N-acyl glycine analysis are reviewed in 
chapter 4. In addition, the appendix summarizes a method for selective, sensitive multiple 
reaction monitoring detection of palmitoylethanolamine, an N-acylethanolamine with 
analgesic and anti-inflammatory properties. 
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Chapter 1 
Metabolism, Physiology, and Analyses of Primary 
Fatty Acid Amides 
 
Adapted from:  Divito, E. B.; Cascio, M.  Metabolism, Physiology, and Analysis of 
Primary Fatty Acid Amides.  Chemical Reviews. (In Press) 
 
1.1  INTRODUCTION 
 Primary fatty acid amides (PFAMs) are a group of lipids that have been identified 
as bioactive lipid signaling molecules.  In this introductory chapter we review the 
progress in identifying metabolism pathways, pharmacological properties, and receptor 
interactions for this group of lipids.  In addition, various modes of separation and 
detection have been developed to study both their biological content and alterations in 
their metabolism, and these studies are also reviewed. 
 Lipids are loosely defined as hydrophobic molecules, typically containing an acyl 
chain or ring structure, that are soluble in organic solvents.  Recently a new classification 
system was developed allowing for a broad definition of lipids that is based on similarity 
in structure and biosynthetic pathways1.  This system ultimately divided lipid molecules 
into eight different classes, including numerous subclasses.  It is easily observed from the 
number of subclasses in each category that lipids comprise a broad range of molecules.  
A few subclasses of the fatty acyls group relevant to this review are shown in Table 1-1.  
A new subclass of lipids, the PFAMs, has been recently identified.  This group consists of 
a carboxamide head group and an acyl tail of various length and unsaturation.   The first 
report of PFAMs was in luteal phase plasma reported in 1989 by Arafat and coworkers2.  
Since this initial discovery, many studies have been published on their interaction with 
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various receptors, including the 5-hydroxytryptamine (5-HT)3-8, cannabinoid9, and ɣ-
aminobutyric acid (GABA) receptors10,11.  Interactions of PFAMs with cannabinoid 
receptors are still somewhat controversial, as oleamide has been shown to weakly 
potentiate (1 µM) or to have no effect on cannabinoid receptors in  
vitro12,13.  Additionally, many observations of behavioral effects upon subcutaneous or 
intravenous injection of oleamide (octahexanoamide, denoted C18:19) have been 
reported.  These responses include analgesic and anti-anxiety14 phenotypes, sleep 
induction15-17, and increased food uptake.18  There also is an implied link between 
oleamide and mood due to the observed potentiation of 5-HT receptors (5-HTR) with 
exogenous application of oleamide14,19. 
 Although studies indicate PFAMs are bioactive signaling molecules, little is 
known about their metabolism or localization in vivo.  This is possibly due to their low 
concentrations in tissue and biological fluids, typically in the nM range2,16,20,21, which 
makes analyses challenging.  Their structural similarity to other lipid subclasses and 
occurrence of isomers within the subclass can make isolation and structural identification 
more complicated.  This review will examine some of the progress made towards 
identifying PFAM metabolic pathways, their physiology and receptor interactions, and 
current methods of analyses.   
. 
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1.2. BIOSYNTHESIS 
 The identification of PFAMs in human plasma in 19892 went largely 
unrecognized until 1995 when Cravatt et al.15 reported increased levels of three PFAMs 
in the cerebral spinal fluid (CSF) of sleep deprived cats.  This finding, in conjunction 
with  several other reports on oleamide (C18:19) and 5-HTR interaction3-11, increased 
interest in the anabolic pathways of PFAMs.  An enzyme involved in the post-
translational modification of peptides, peptidylglycine α-amidating monoxygenase 
(PAM), converts peptidyl glycines to their active amidated form.  Merkler et al.22 were 
Lipid Subclass 
Common 
Name 
(CX:Yz) 
Structure 
Fatty Acids 
(FA) 
Oleic acid 
(C18:19) 
 
Primary Fatty Acid Amides 
(PFAMs) 
Oleamide  
(C18:19) 
 
Erucamide 
(C22:113) 
 
Linoleamide 
(C18:29,12) 
 
N-acyl Glycines 
(NAGs) 
Oleoylglycine 
(C18:19) 
 
N-acyl Ethanolamines 
(NAEs) 
Anandamide 
(C20:45,8,11,14) 
 
 
Table 1-1.  Representative structures from the FA, PFAM, NAG, and NAE 
subclasses of lipids. The common name is given for each structure along with 
the typical lipid abbreviation CX:Yz.  C indicates the carbon acyl chain starting 
from the head group position with X being the number of carbon atoms in the 
chain.  Y is the number of unsaturation points and z indicates the position(s) of 
unsaturation. The orientation of unsaturated bonds are cis unless otherwise 
noted (e.g., C18:19 trans). 
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the first to report that PAM also converts N-myristoylglycine (C14:0) to the primary 
amide, myristamide.  This led the authors to hypothesize that PAM could amidate other 
fatty glycines to their corresponding primary amide form.  In a subsequent work, a broad 
range of fatty glycines, from formylglycine to linoleoylglycine, were converted to the 
primary amide form by purified recombinant type A rat PAM23,24.  The apparent affinity 
of these substrates for PAM varied widely, but generally increased as the acyl chain 
length of the substrate increased.  The Km for longer chain length substrates were 
generally equal or greater than that of a previously characterized “good” peptide 
substrate, D-Tyr-Val-Gly.  Oxygen and glyoxylate levels were measured to quantitate 
activity of PAM, and NMR studies confirmed the conversion of the fatty glycine to its 
PFAM.  During monitoring of oxygen and glyoxylate, oxygen levels depleted rapidly 
while glyoxylate production, from the oxidative cleavage of the fatty glycine, 
accumulated more slowly.  This supported a hypothesis that the fatty glycine first goes 
through an intermediate form before oxidative cleavage by peptidyl-α-hydroxyglycine α-
amidating lysase (PAL), the second domain of PAM.   The intermediate was identified by 
NMR analysis as N-acyl-α-hydroxyglycine23.  In vitro reactions of PAM and various fatty 
glycines were analyzed by liquid chromatography and UV detection, and the resulting 
three peaks were identified as the fatty glycine, the N-acyl-α-hydroxyglycine, and the 
PFAM.  When a PAL inhibitor was added to the incubation mixture the levels of fatty 
glycine and the intermediate N-acyl-α-hydroxyglycine increased and PFAM levels were 
decreased as compared to the incubation mixtures without inhibitor25.  Similar results 
were observed in N18TG2 mouse neuroblastoma cells
26.  The authors proposed a 
biosynthesis pathway where a fatty acid is converted to a fatty-CoA by acyl-CoA 
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transferase.  The fatty-CoA then is converted to a fatty glycine by glycine N-acyl 
transferase (GLYAT) and the fatty glycine proceeds to the PFAM through the actions of 
PAM (see Scheme 1). 
 Mueller and coworkers have reported enzymatic conversion of both oleoyl-CoA 
and oleoyl glycine to oleamide by cytochrome c27,28.  In both cases, the presence of 
oleamide was confirmed by TLC separation, liquid chromatography with UV detection, 
and tandem mass spectrometry.   In regard to conversion of oleoyl-CoA to oleoyl glycine, 
maximal conversion rates were observed with 300 µM glycine and 2 mM hydrogen 
peroxide under physiological conditions (37oC and pH 7.6)28.  Similar conditions were 
reported for the synthesis of oleamide from oleoyl-CoA, except that ammonium chloride 
was 125 mM for maximal activity27.  Similar experiments were conducted by McCue et 
al. demonstrating that arachidonoyl-CoA could also be converted to the fatty glycine by 
cyctochrome c29.  Ammonium has been implicated as the source of nitrogen in the 
amidation reaction producing PFAMs30, however the enzyme responsible for the 
conversion was not identified.    Additionally, oleic acid was unable to be converted 
directly to either oleoylglycine or oleamide, consistent with the proposed pathway of 
Merkler and coworkers24 wherein the fatty-CoA is an essential component in oleamide 
biosynthesis.    
 Bile acid CoA:amino acid N-acyl transferase (BAAT) has also been found to 
catalyze the conversion of fatty-CoA substrates to fatty glycines31.  This enzyme 
displayed highly variable activity for acyl chain lengths of 16 to 22, and its activity was 
markedly decreased when any degree of unsaturation was present.  The relative 
enzymatic activity increased for saturated fatty-CoAs of 22 to 26 carbon length.  This 
 6 
enzyme, therefore, might not aid in the formation of oleamide, but of other long chain 
PFAMs.   
 In 2010, Waluk et al.32 demonstrated that glycine N-acyltransferase-like 2 
(GLYATL2) showed specificity with glycine conjugation of fatty-CoAs of medium chain 
length (C8 to C18).  GLYAT is known to have highest activity with benzoyl-CoA, but is 
also capable of conjugating glycine to short chain fatty-CoAs (less than C8)33.  
GLYATL2 showed the highest activity with C18:1-CoA (Km = 4 µM) to produce 
oleoylglycine.  Little to no activity was observed with substrates with fewer than an 8 
carbon acyl chain, in the absence of conjugated glycine, and with alanine, serine, or 
taurine substituted for the glycine moiety.  Additionally, some inhibition was observed 
with substrate concentrations above 50 µM.  Interestingly, this enzyme was found in the 
endoplasmic reticulum localized in the salivary gland, trachea, spinal cord, and skin.  
Measurement of levels of NAGs by LC-MS in selected ion mode found highest NAG 
levels in the spinal cord and skin34, similar to reports of GLYATL2 localization, 
providing evidence that this is a good candidate enzyme for in vivo synthesis.  It is 
important to note that rodents do not possess the ortholog to hGLYATL2.  They do 
express the orthologs for hGLYAT and hGLYATL3, however the latter has not yet been 
characterized for acyl-glycine conjugating activity.  
 Several other reports have identified a relatively new pathway for synthesis of 
NAGs from NAE precursors.  The first report, by Burstein and co-workers35, identified 
via radiochromatograms that liver cell extracts produced N-arachidonoylglycine when 
anandamide was present.  In experiments with RAW 264.7 murine macrophage cells, it 
was established that a deuterium labeled anandamide produced a likewise deuterium 
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labeled N-arachidonoylglycine as determined with LC-MS/MS studies36.  The authors 
also demonstrated that incubation of cells with arachidonic acid did not produce N-
arachidonoylglycine.  Application of N-arachidonoylglycine to cell cultures also did not 
result in the production of neither arachidonic acid nor anandamide.  To support that 
alcohol dehydrogenase (ADH) was the enzyme responsible for the conversion of 
anandamide to N-arachidonoylglycine; the ethanolamide moiety of anandamide was 
deuterium labeled.  Analysis of the products showed deuterium labeling of N-
arachidonoylglycine consistent with the mechanistic actions of ADH.  Incubations of 
anandamide, glycine, and recombinant FAAH were unable to produce N-
arachidonoylglycine, therefore ruling out this enzyme as a participant in the conversion. 
These findings have been further supported by in vitro studies of purified ADH 
isoforms.  ADH7 was used with anandamide (1-8 M) to determine if this enzyme 
catalyzes the production of N-arachidonoylglycine from anandamide37.  Products 
analyzed by LC-MS/MS in MRM mode revealed a match to the standard N-
arachidonoylglycinal.  In incubations of ADH7 with N-arachidonoylglycinal, N-
arachidonoylglycine product was only detected in the presence of enzyme.  ADH5 was 
found to be inactive for conversion of anandamide to the glycinal or glycine derivative.  
However, these studies were conducted under non-physiological conditions. 
ADH3 was found to convert NAEs (C2 – C20) to their corresponding N-
acylglycinals with Km and Vmax values generally decreasing with increasing chain 
length38.  These studies were confirmed with analysis by HPLC, GC-MS, and carbon 
NMR.  Km and Vmax values were unable to be determined for carbon chains above 12 due 
to low solubility.  However, acetylethanolamine values were Vmax/Km = 2.7 sec
-1M-1, Km 
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= 450 mM, Vmax = 1.9 µmol/min×mg and lauroylethanolamine were Vmax/Km = 160 sec
-
1M-1, Km = 0.033 mM, Vmax = 0.14 µmol/min×mg.  The fatty-glycinal was found to be 
the primary product and conversion to the fatty-glycine was determined to be due to non-
enzymatic aldehyde dismutation. Docking experiments indicate the hydroxyl group of the 
NAE coordinating with Zn(II) of the active site akin to previously studied ADH3 
substrates39,40. The authors suggest that the relatively low Km and Vmax values make it 
unlikely that this enzyme plays a significant role during in vivo conversion of NAEs.  
 The proposed intermediate of oleamide, oleoylglycine, was studied to determine 
the physiological effects and the effect on oleamide levels41.  Injection reduced 
locomotion and core body temperature.  After euthanasia, oleamide levels were found to 
not increase in serum, suggesting oleoylglycine has the ability to induce similar 
physiological effects as those observed with oleamide.  Fatty glycines might not be 
requisite intermediates in the metabolic pathway of PFAMs.  However, it is still unclear 
how this pathway is regulated in vivo. 
Thus, current evidence suggests that PFAM synthesis does not proceed directly 
from the free fatty acid, but must first be converted to a fatty-CoA substrate for further 
modification.  The next step in the proposed biosynthetic pathway is controversial, as it is 
not known at this time if GLYAT, cytochrome c, BAAT, an unidentfied enzyme, or a 
combination is responsible for the conversion to the fatty glycine.  If the fatty glycine is 
the anabolic intermediate, then conversion to the PFAM has been demonstrated with both 
PAM and cytochrome c.  However, the results of Mueller et al.28 suggest that an 
alternative pathway, to that proposed by Merkler22, could also exist leading from the 
fatty-CoA directly to the PFAM (see Scheme 1-1 for a pathway summary).  It is also 
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unclear if glycine, ammonia, or some other molecule may be the source of nitrogen in the 
amidation reaction of PFAMs.  For example, addition of glutamine to rat brain 
homogenate resulted in modest increase in levels of oleamide30. Further studies are 
essential to provide a better understanding of the anabolic pathway for PFAMs, as defects 
in their metabolism may contribute to disease states and PFAMS clearly play an 
important role in health and fitness. 
 
 
 
1.2.1. Degradation by Fatty Acid Amide Hydrolase (FAAH) 
 FAAH activity has been extensively reviewed42-46, and is, therefore, only briefly 
discussed.  FAAH is a 65 KDa integral membrane protein that enzymatically degrades 
fatty acid amides, such as anandamide and oleamide, to their respective fatty acid47,48 
(Scheme 1-2).  Site directed mutagenesis studies have identified three consensus amino 
Scheme 1-1.  Proposed pathways of PFAM anabolism suggest a starting product of a fatty acyl 
CoA substrate being converted to either to the related N-acyl glycine intermediate or directly to 
the PFAM.  The substrates shown are of ambiguous length; however note that n (the number of 
carbons) does not change according to any of the proposed mechanisms.  The enzymes shown 
(GLYAT, cytochrome c, PAM, and BAAT) in the conversion of the fatty-CoA to the fatty 
glycine or fatty amide are still debated in vivo. 
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acids (K142, S217, and S241 in rFAAH) that are essential for enzyme activity, and these 
have been termed the Ser-Ser-Lys catalytic triad49.  Rat FAAH has been co-crystallized 
with inhibitor methoxy arachidonyl phosphonate and solved to a 2.8 Å resolution50.   In 
2006, FAAH-2, another enzyme that degrades fatty acid amide substrates, was identified 
and has 20% sequence identity with FAAH.  FAAH-2 has similar hydrolysis rates with 
oleamide (FAAH-1 9.7+/-0.8 and FAAH-2 8.4+/-0.8 nmol/min×mg, respectively) but 
could not degrade anandamide as efficiently as FAAH-1 (FAAH-1: 17 +/- 1, and FAAH-
2: 0.46 +/- 0.04 nmol/min×mg, respectively)51.  These two enzymes were found to have 
slightly different substrate selectivity, with FAAH-1 preferentially degrading poly-
unsaturated substrates while FAAH-2 degraded mono-unsaturated substrates.  The two 
enzymes seem to respond similarly to known inhibitors of FAAH-1 (see references 42-46 
for lists of inhibitors).  Interestingly, FAAH-2 sequence matches were found in humans 
but not in mice or rats, thus care should be taken in direct pharmacological comparisons 
across species and subtypes. 
 
 
 
Scheme 1-2.  Degradation scheme of (A) oleamide and (B) anandamide with enzyme FAAH.  The 
amide substrates are degraded via hydrolysis to their corresponding fatty acid.  For a catabolic 
mechanism involving FAAH see references 42 and 45. 
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1.3.  FATTY ACID AMIDE EFFECTS ON PHYSIOLOGY 
 The most well-known physiological effect of PFAMs is their sleep inducing 
properties.  Lerner et al. initially reported the increased concentration of a lipophilic 
molecule in the cerebrospinal fluid of sleep deprived cats, which they termed 
cerebrodiene16.  The structure was later verified as oleamide, and a second component 
was identified as erucamide15.  Similar studies have also shown an increase in oleamide 
in the cerebral spinal fluid in hibernating squirrels52.  Injection of 5 mg/kg of oleamide in 
rats induced hypolocomotion and sleep-like behaviors.  Other reports have shown that 
oleamide injection in mice increases sleep latency and hypomobility11,14,19,53,54.   Oleic 
acid and elaidamide (C18:19 trans) did not cause the sleep inducing properties of oleamide, 
consistent with specific allosteric interactions of this PFAM with a target receptor. The 
sleep induction process was not accompanied with changes in heart rate or blood 
pressure, however a concentration dependent decrease in body temperature (2oC at 20 
mg/kg dose) was observed as soon as 30 minutes after injection17,54.  The mechanism by 
which oleamide acts to induce sleep is currently unknown. 
Due to the structural similarity of oleamide and anandamide, other physiological 
effects of oleamide related to cannabinoid receptor interaction were investigated.  Similar 
to the effects of anandamide, oleamide was found to induce overeating in Wistar rats at 
all doses tested (0.5-4 mg/kg).  It is still uncertain if oleamide is able to interact directly 
with cannabinoid receptors in vivo or if the presence of oleamide increases the relative 
half-life of anandamide to yield secondary physiological effects.    
 Erucamide, also found in cerebral spinal fluid with oleamide, was previously 
isolated and purified from bovine omentum55.  This lipid was found to promote 
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angiogenesis in regenerating skeletal muscle, chick chorioallantoic membrane, rat cornea, 
and mouse dorsal air-sac when applied in microgram quantities.  Related PFAMs, with 
varied acyl chain length, were also tested to determine their ability to promote 
angiogenesis.  Similar to other reports previously discussed, amides with acyl chains 
shorter than 16 carbons showed weak or no angiogenesis, while longer chains approached 
activity comparable to erucamide.  The increase in angiogenesis was explored to 
determine if this property was an effect of increased cellular proliferation.  No increase in 
proliferation was observed with erucamide levels < 0.1 mg/mL.  These effects were not 
affected by addition of glucocorticoid, suggesting that erucamide-induced angiogenesis is 
not due to an inflammatory response.  These observations were later replicated by 
Mitchell et al. when studying the effect of erucamide on regenerating skeletal muscle56.  
In samples where erucamide seemed to increase angiogenesis in skeletal muscle the 
standard deviation was large making interpretation difficult.  Additionally, erucamide 
application did not change the type of cells present or increase regeneration, consistent 
with observations of Wakamatsu et al.55. 
 NAGs have also been shown to have biological effects similar to PFAMs. 
Oleoylglycine has been shown to induce hypothermia and hypomotility in rats to a 
comparable potency as oleamide41.   N-arachidonoylglycine has been demonstrated to 
dose dependently attenuate T lymphocyte proliferation35.   This substrate was also found 
to reduce IL-1β secretion from human peripheral blood mononuclear cells with treatment 
at 1 and 10 µM.  Additionally, 0.43 µg palmitoylglycine administered via intradermal 
injection suppressed the response to heat stimulus at 45-52oC57 and 275 nmol of N-
arachidonoylglycine reduced formalin-induced pain response.  In the following sections 
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we focus on the observed effects of PFAMs and NAGs on metabotropic and ionotropic 
receptors, transporters, and gap junction proteins.  These results are also summarized in 
Table 1-2. 
 
1.3.1. Serotonin Receptors 
 After the discovery that oleamide accumulates in the cerebral spinal fluid of sleep 
deprived mammals15,16 many reports were published on the effect of oleamide on 
serotonin (5-hydroxytryptamine) receptors (5HTRs), due to the link between 5-HTR 
activity and sleep58-60.  c-Fos, a protein that regulates transcription, is found to be 
upregulated in specific brain regions of rat during night hours7.  Intraperitoneal injections 
Target Substrate Effect 
Maximal 
Response 
EC50 Reference 
5-HT1AR Oleamide Potentiates 100 nM - 3 
5-HT2AR Oleamide Potentiates 100 nM - 3, 7 
5-HT2CR Oleamide Potentiates 100 nM - 5, 3 
5-HT3R Oleamide No effect - - 5 
5-HT7R Oleamide Inhibits 100 nM - 7 
CB1R Oleamide 
No effect 
Potentiates 
-  
10 µM* 
13 
12 
GABAA R Oleamide 
No effect 
Potentiates 
(α1β1γ2s) 
Potentiates 
(α1β2γ2L) 
Potentiates 
 
500 nM 
 
 
 
28 µM 
 
15 µM 
5 
66 
 
64 
 
10 
α1 GlyR Oleamide Potentiates - 22 µM 64 
Gap 
Junction 
Oleamide 
Inhibits 100 µM 50 µM 71 
GLYT2a Arachidonoylglycine Inhibits - 5.1 µM* 67 
GLYT1b Arachidonoylglycine No effect - - 67 
GAT1 Arachidonoylglycine No effect - - 67 
TRPV1 Anandamide Potentiates - 5-12 µM 73, 77 
Table 1-2. Summary of effects of oleamide, N-arachidonoylglycine, and anandamide 
on various receptors, transporters, and gap junction proteins.  The * denotes values 
reported as an IC50.  Orphan receptors were excluded due to incomplete 
characterization at present time. 
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of oleamide administered to rats induced a normal sleep-like state during daytime hours. 
Immunohistochemical staining and in situ hybridization indicated that c-Fos expression 
was increased in rat brain 45 minutes to 2 hours after injection with oleamide7.  
Expression of 5-HT7R was identified in the same regions as c-Fos upregulation.  The 
most prevalent areas of c-Fos upregulation as a result of oleamide treatment were the 
cerebral cortex, hypothalamus, and thalamus.  Injections of oleic acid increased c-Fos 
expression as well; however the increase was not as significant as that observed with 
oleamide. 
Huidobro-Toro et al. reported the effects of oleamide on Xenopus oocytes 
expressing either 5HT2AR or 5HT2CR by observing chloride currents produced by 
downstream signaling via two electrode recordings.  Oleamide reversibly potentiated 
both serotonin subtypes via altered efficacy of 5HT2AR and reduction of the EC50 of 
5HT2CR.  Co-treatment of the oocytes with kainate or carbachol, competitive inhibitors of 
5HTR, did not alter the effects of oleamide suggesting oleamide acts at an allosteric site.  
Changing the cis- double bond to a trans- configuration, altering the head group to a 
carboxylic acid from the carboxamide, or movement of the double bond eliminates the 
potentiation effect observed with oleamide (stearamide (C18:0) exhibits inhibitory 
effects).  
 Boger et al. reported maximal potentiation of subtypes 5HT1AR and 5HT2AR 
when 100 nM oleamide was co-administered with 5HT3.  Receptor activity was measured 
by calorimetric assay for β-galactosidase in NIH 3T3 cells expressing 5-HT2AR, or in 
RAT-1 cells expressing 5-HT1AR and the β-galactosidase gene.  Of the lipid variants 
tested, oleamide was found to have the highest activity.  Patterns in activity were 
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discerned by systematic alternation of oleamide’s structure, as compounds containing an 
olefin at a Δ9 from the methyl terminus showed small potentiation while compounds with 
the olefin at Δ9 from the head group position were inactive.  Movement of the double 
bond further from the carboxamide produced inactive compounds, while positioning the 
double bond closer to the carboxamide resulted in inhibitory effects.  An overall increase 
in unsaturation points typically decreased potentiation.  These results were mimicked in 
both receptor subtypes, however, 1A receptor subtypes were more tolerant of structural 
changes to oleamide than 2A receptor subtypes. 
 Oleamide was also found to increase phosphoinositide hydrolysis in 5HT2AR 
when co-administered with 5HT6.  As in previous reports, in the absence of 5HT 
oleamide had no substantial effect on phosphoinositide hydrolysis and increased cAMP 
accumulation.  However, oleamide induced inhibition of cAMP in the presence of high 
concentrations of 5-HT (1 mM). Oleamide was shown to inhibit cAMP accumulation and 
radiolabeled 5-HT binding to 5HT7R in a concentration-dependent manner
6,8. Clozapine, 
a high affinity inhibitor of 5-HT7R, was unable to block the increase in cAMP in response 
to oleamide treatment. It was, thus, concluded that oleamide acts at an allosteric site, 
which is in agreement with the results previously discussed4.   
 
1.3.2. Cannabinoid Receptors 
 Because PFAMs are structurally similar to the N-acylethanolamine (NAE) fatty 
acyl subclass, such as the endocannabinoid anandamide, efforts have been made to 
determine if oleamide is an endogenous ligand for cannabinoid (CB) receptors.  Reports 
on oleamide interaction with CB1 receptors have provided conflicting results thus far.  
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Oleamide causes concentration-dependent vasorelaxation of rat mesenteric resistance 
arteries9,61,62.  In the presence of AM251, a CB1 receptor subtype inhibitor, but not 
AM630, a CB2 subtype receptor inhibitor, the vasorelaxation was attenuated, suggesting 
that oleamide may induce these effects partially through action of CB1 receptors
9.  These 
effects were also reduced in the presence of O-1918, an inhibitor of the non-CB1/CB2 
receptor, and with inhibitors of the vanilloid receptor 1 (TRPV1).  The attenuation was 
not observed in the presence of CB1 receptor inhibitor when the mesenteric arteries were 
denuded of endothelium. The vasorelaxation effect was also reduced in the presence of 
nitric oxide synthase inhibitor, L-NAME, and with K+ and Ca+ channel inhibitors, 
indicating that oleamide may have several modes of action with respect to 
vasorelaxation9,62.  Addition of a fatty acid amide hydrolase inhibitor had no effect on the 
ability of oleamide to induce vasorelaxation9.  Since formation of the catabolic 
metabolite, oleic acid, is inhibited in these studies it is concluded that carboxamide 
functionality is necessary for the vasorelaxation response.  As expected from the FAAH 
study, exogenous application of oleic acid to rat mesenteric resistance arteries had no 
observable effect9.  Several other reports have shown low affinity (IC50 10 µM
12) or 
negligible binding of oleamide to CB1 receptor
13.  It is unclear if solubility is contributing 
to the conflicting results, as some samples are prepared in an organic solvent-containing 
solution while others dissolved the lipid agent in saline.  However, the physiological 
concentration of oleamide and other PFAMs in mesenteric arteries or heart, as well as 
other organ systems, is not reported.  Interestingly, PAM activity was found to be 1000 
times higher is the atrium, while no amidated peptides have been reported in that region.  
Since PAM is the proposed anabolic enzyme for PFAMs it is possible that PFAM levels 
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in heart may be higher than previously reported in cerebral spinal fluid or plasma (nM).  
Knowledge of these levels will aide in determining if PFAMs are endogenous 
endocannabinoids that can invoke signaling in vasorelaxation pathways.  Additionally, 
this information may provide insight to other physiological roles as well as their 
anabolism in vivo. 
 
1.3.3. GABA and Glycine Receptors 
 Oleamide administration via intraperitoneal injection in mice shows analgesic-like 
effects19 and, as previously stated, is shown to increase in the cerebral spinal fluid of 
animals subjected to 6 or more hours of sleep deprivation15.  GABA receptors (GABAR) 
are targets for various sedatives, such as barbiturates and anesthetic steroids63, raising 
speculation that oleamide may well interact with GABARs.  In GABAAR β3 subunit 
knockout mice, intraperitoneal injection of oleamide (0.8 mg/kg or 1.6 mg/kg) did not 
produce a decrease in sleep latency that is typically observed in wild type mice treated 
with oleamide as compared to wild-type controls11.  Additionally, no other hypnotic 
effects were observed in the knockout mice versus controls not injected with oleamide.  
Therefore, it seems that GABAR may play a role in the oleamide-induced signaling 
pathway that causes sleep.  Other reports have also shown that oleamide’s effects may be 
subunit-dependent.  Electrophysiological measurements have shown that oleamide 
potentiates chloride currents in α1β1γ2 or α1β2γ2 GABARs with an EC50 of 
approximately 20 µM10,64-66.  Oleamide alone had no effect on current as compared to 
controls, and current enhancement was not observed with the α1β2 receptor type10.  
Radiolabeled binding assays indicated that binding of GABA was not affected by 
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oleamide application19,64.  The EC50 for GABA was reduced, while the Hill slope was 
unaffected by exogenous application of oleamide, suggesting that oleamide works 
through an allosteric-type mechanism64.  Oleamide was found to potentiate α1 glycine 
receptor homopentamers, with a similar EC50 to GABAR, but overall current 
enhancement was less marked than with GABARs.  It has been suggested that receptor 
potentiation could be affected by second messenger signaling or altered receptor 
phosphorylation53.  Such changes in phosphorylation have been observed in α1 
connexins67 (see 3.5  Gap Junctions and Ca2+ Signaling).  However, these possibilities 
are unexplored for GABARs and GlyRs.  
 
1.3.4. Glycine Transporters 
  In studies of the glycine transporter 2a (GLYT2a), co-application of glycine (30 
uM) and N-arachidonoylglycine (10 µM) to Xenopus oocytes reduced the amplitude of 
the glycine mediated current measured by two electrode voltage clamp68,69.  Washout of 
N-arachidonoylglycine and subsequent application of glycine produced current levels 
similar to those observed before exposure to N-arachidonoylglycine.  No difference in 
current amplitude was observed with treatment with staurosporine, thus, the observed 
inhibition by N-arachidonoylglycine is not linked to protein kinase C activation.  In 
addition, N-arachidonoylglycine treatment also reduced the amount of glycine uptake.  
Given these observations, it was concluded that reduction in glycine currents was a result 
of  N-arachidonoylglycine inhibition of GLYT2a activity. Concentration response data 
for glycine in the presence and absence of 10 µM N-arachidonoylglycine revealed that 
the substrate acts as a reversible, non-competitive inhibitor with an IC50 = 5.1 ± 3.1 µM.  
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Similar experiments show that N-arachidonoylglycine is not a substrate for GAT1 and 
GLYT1b. 
 
1.3.5. Gap Junctions and Ca2+ Signaling 
  Oleamide, and another structurally similar PFAM, linoleamide (C18:29,12), were 
studied to determine their effect on gap junction communication and Ca2+ signaling.  
Application of 50 µM oleamide abolished gap junction transfer of Lucifer Yellow dye 
and conductance in cultured rat glial cells67,70.  Oleic acid and elaidamide (C18:19 trans) 
had no effect on dye transfer, nor conductance, even at concentrations greater than 50 
µM.  Other structural analogs, such as cis-8-octadecenamide, cis-11-octadecenamide, or 
the ethanolamine derivative, were effective at blocking gap junction communication, but 
with less potency than oleamide67.  Subsequent studies using a broad range of analogs 
found that the cis-9 olefin position and stereochemistry determined the magnitude of 
PFAM effect on gap junction activity in glial cells70.   Moving the double bond “up or 
down” the chain, as well as changing the stereochemistry from cis- to trans-, reduced the 
observed inhibition of gap junctions.  Erucamide (C22:113), a natural PFAM containing 
the typical positional isomer of C22:1, had negligible inhibitory effects, while a synthetic 
derivative, cis-9-docosenamide (C22:19), inhibited gap junction activity to levels 
comparable to oleamide.  Variations in the acyl tail length were tolerable within a narrow 
range (C16 to C20).  Shortening the acyl tail length to C14 reduced the inhibitory effect, 
while acyl tails longer than C20 also showed diminished inhibition.  All of the poly-
unsaturated fatty acids studied were less potent than oleamide, with the exception of 
arachidonamide (C20:48,11,14, 16) which showed 90-100% inhibition at 20-100 µM70.  
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Some tolerance was observed when the head group of oleaminde was altered.  The ethyl 
ester and a sarcosine derivative retained a portion of activity, but the NAG, oleoylglycine 
(a suspected anabolic precursor to oleamide), did not inhibit gap junction communication.  
This data supports the hypothesis that amidation of these species confers biological 
activity.  Other derivatives also retained similar inhibitory properties with respect to gap 
junctions if the structural alterations contained a π-electron system at the Δ9 position 
and/or were perturbed such that the molecule adopted a “hairpin” configuration70.  
 Calcium signaling can traffic through gap junctions, therefore calcium wave 
propagation was investigated in rat glial cells treated with oleamide, a gap junction 
inhibitor67.  Oleamide and anandamide were found to have no effect on calcium wave 
propagation, suggesting that gap junction inhibition is not caused by molecular 
“blocking” or insertion into the junction.   Oleamide was found to block gap junction 
communication of cells with α1 and β1 connexin similarly, while oleic acid and 
elaidamide (C18:19 trans) had no effect. Since α1 connexin may be either non-, mono- or 
di-phosphorylated, changes in phosphorylation were tested in response to oleamide 
pretreatment.  In cells exposed to oleamide, there was a significant decrease in the di-
phosphorylated isoform.  After washing the cells to remove oleamide, the di-
phosphorylated isoform returned to basal levels.  To our knowledge this is the sole report 
of PFAMs altering protein phosphorylation. 
50 µM oleamide caused an increase in internal calcium of T24 and BFTC bladder 
cancer cells, human MG63 osteoblast-like cells, canine MDCK renal tubular cells and rat 
PC12 pheochromocytoma cells71. T24 cells had the largest oleamide-induced internal 
calcium increase of these cell lines.  The effect was concentration dependent between 10-
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100 µM with an EC50 of 50 µM.  Linoleamide, a congener of oleamide, was found to be 
more potent, with an EC50 of 30 µM.   The source of internal calcium increase was found 
to be mainly from influx, as determined by removing external calcium71,72.  However, this 
concentration increase was found to be partially due to release of endoplasmic reticulum 
stores, as cell pretreatment with thapsigargin, an endoplasmic reticulum pump inhibitor, 
blocked the oleamide or linoleamide-elicited effect. 
Palmitoylglycine treatment (10 µM) of F-11 cells was found to increase calcium 
influx (EC50 = 5.5 µM) as measured by fluorescence with the calcium fluorophore, Fura-
257.  Stearoylglycine and stearic acid were found to marginally elevate calcium influx.  
Other related fatty glycines such as, oleoylglycine, N-arachidonoylgylcine, 
docosahexaenoylglycine, as well as free glycine were unable to affect calcium levels at 
concentrations up to 50 µM.  10 µM of ruthenium red and 1 mM La3+, abolished calcium 
response due to palmitoylglycine treatment and pertussis toxin attenuated the effect.  2 
µM treatment with ω-conotoxin MVIIC or ω-conotoxin GVIA, voltage-gated calcium 
blockers, did not affect the influx of calcium. 
 
1.3.6. Transient Receptor Potential Vanilloid Receptors 
Transient receptor potential (TRP) cation channels are key receptors in the 
perception of pain and are activated by noxious stimuli including heat, cold, pH, and 
lipidergic substances.  Here we will discuss briefly their interaction with various N-acyl 
ethanolamines and N-acyl amino acid derivatives.  For a more complete picture of TRP 
receptors, please see the following reviews73-76.   
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 Anandamide (C20:4 NAE) was found to induce vasodilation in rat hepatic and 
small mesenteric arteries and guinea-pig basilar artery, as well as increase calcitonin 
gene-related peptide (CGRP) and increase tissue content of cAMP in rat hepatic artery 77.  
Pretreatment with capsaicin and 8-37 CGRP (vasodilator neuropeptide anatagonist) 
abolished anandamide induced relaxation and capsazepine (vanilloid receptor 
anatagonist), inhibits  vasodiliation and attenuates release of CGRP.  These effects were 
shown to be TRPV specific, as SR141716A (CB1 receptor antagonist), ω-conotoxin 
GVIA, MVIIC, nor nimodipine (voltage-gated calcium blockers) did not block 
anandamide induced relaxation.  2-arachidonylglyercol and palmitylethanolamide were 
unable to elicit a response.  Similar activity with other NAEs on TRPV has been reported.  
Linolenoylethanolamine (C18:3), linoleoylethanolamine (C18:2), and 
oleoylethanolamine (C18:1) were found to induce concentration dependent vasodilation 
in rat mesenteric artery, which was blocked by capsazepine and arteries pretreated with 
capsaicin78.  The observed relaxation of arteries treated with oleoylethanolamine was 
nearly absent in TRPV1 knockout mice.  Linolenoylethanolamine, 
linoleoylethanolamine, oleoylethanolamine, anandamide, and N-
Docosatetraenylethanolamine (C22:4) dose-dependently increased intracellular calcium.  
LC-MS/MS experiments revealed that stearoylethanolamine (C18:0), 
oleoylethanolamine, and linoleoylethanolamine were found in higher levels in mesenteric 
arteries compared to anandamide (21, 16, and 19 pmol/mg protein respectively), however 
activity in calcium assays required at least one unsaturation point. 
 While the above experiments with NAEs required low micromolar quantities, 
some N-acyl dopamines were found to have a much higher potency.  N-arachidonoyl 
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dopamine was found to increase intracellular calcium in HEK293 cells overexpressing 
hVR1 (EC50 = 40 nM) and rVR1 (EC50 = 48 nM)
79.  This increase was abolished by 
iodoresiniferatoxin.  Intradermal injection of N-arachidonoyl dopamine (1.5 µg) in the 
hind paw of Sprague-Dawley rats resulted in thermal hyperalgesia.  Analysis via MS 
showed the highest concentrations of N-arachidonoyl dopamine in the striatum, 
hippocampus, and cerebellum.  Similar experiments were conducted with N-oleoyl 
dopamine, N-palmitoyl dopamine (C16:0), and N-stearoyl dopamine (C18:0)80.  In 
agreement with previous trends, the saturated compounds, N-pamitoyl dopamine and N-
stearoyl dopamine, were found to be inactive in calcium mobilization and thermal 
hyperalgesia assays.  N-oleoyl dopamine increased calcium mobilization (EC50 = 36 nM) 
and thermal hyperalgesia (EC50 = 0.72 µg) with a somewhat greater potency than N-
arachidonoyl dopamine.   
 Recently Bradshaw and colleagues have reported striking similarities between the 
activity profiles of palmitoylglycine, an NAG, and TRPC5 and this hypothesis is 
currently under investigation by their group74.  Though not data currently exists for 
activation of TRP receptors and NAGs or PFAMs, the striking similarity of these lipid 
subclasses and the above lipidergic ligands makes it intriguing to speculate that these 
compounds may, too, be endogenous activators. 
 
1.3.7. Interaction with Orphan G-protein Coupled Receptors 
 Recently there has been an effort to identify and match orphan receptors to 
physiologically relevant ligands.  GPR92 is an orphan receptor that is part of the 
rhodopsin-like GPCR family.  It has been shown by reversed transcription PCR to have 
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the highest mRNA levels in dorsal root ganglia in the nervous system, spleen, stomach, 
intestine, thymus, and kidney69,81,82.    As previously mentioned, N-arachidonoylglycine 
shows similar distribution levels as GPR9234.    In studies of CV-1 cells, addition of N-
arachidonoylglycine increased levels of inositol phosphate in a concentration dependent 
manner, with an EC50 > 50 µM as measured in radioactivity assays
81.  This increased 
inositol phosphate production was abolished by treatment with a phospholipase C 
inhibitor, U73122.  Additionally, N-arachidonoylglycine caused a dose-dependent 
increase in intracellular calcium concentration that was not blocked by treatment with 
pertussis toxin, as measured in DRG neurons. N-arachidonoylglycine was not, however, 
able to affect levels of cAMP.  Molecular modeling and site-directed mutagenesis 
identified residues Thr97, Gly98, and Phe101 on transmembrane domain 3 of GPR92 as 
interacting with N-arachidonoylglycine. 
 N-arachidionoylglycine was also found to interact with GPR18, an orphan 
receptor expressed in T and B cells69,83.   Treatment with 10 µM N-arachidionoylglycine 
increased intracellular calcium release in L929 cells, and this effect was also observed in 
K562 and CHO cells with a 2 to 3 fold higher response83.  Unlike GPR92, treatment of 
cells expressing GPR18 with 100 nM N-arachidonoylglycine had a 70% inhibition of 
cAMP production (IC50 = 20 nM).  However, other groups using techniques like 
PathHunter assays and electrophysiology have disputed N-arachidonoylglycine activation 
of GPR1884,85.  
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1.4. ANALYSES METHODS 
 PFAMs and NAGs have shown a wide variety of physiological effects on receptor 
activity and animal behavior.  However, it is often difficult to analyze the content and 
identity of these bioactive lipids.  PFAMs are generally found at nM levels at 
physiological levels and absorb very weakly in the UV-Visible region making detection 
and identification using conventional methods challenging.  Additionally, NAGs have 
been reported in ranges of pmol of amide per gram of tissue analyzed.  In the following 
sections we review methods for the isolation, separation, and detection of PFAMs and 
NAGs from biological samples.    
 
1.4.1. Chromatographic Separation Techniques 
 Sample preparation, in terms of extraction and/or isolation of PFAMs, is the 
preceding step in any chromatographic separation technique.  This step can be 
challenging, as many of the fatty acyl subclasses share similar properties with PFAMs.  
The most common extraction for PFAMs is a Folch-Pi extraction86, which isolates the 
fatty acyls, triacylglycerols (TAGs), diacylglycerols (DAGs), monoacylglycerols 
(MAGs), N-acyl glycines (NAGs), PFAMs, and N-acylethanolamines (NAEs).  A 
toluene:acetone (4:2) solvent mixture was used to extract erucamide from various organ 
tissue87.  Extraction is sometimes accompanied by an isolation step, typically utilizing 
solid phase extraction (SPE) methods88-90.  An SPE method for isolation of only PFAMs 
from standard lipid mixture and N18TG2 mouse neuroblastoma cells was detailed by 
Sultana et al.89    PFAM recoveries were 70% or greater for 0.2-20 µg of amide loaded 
onto the SPE columns and fractional lipid content was verified by TLC.  This method 
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could be used for isolation of any of the nine lipid subclasses (fatty acids, PFAMs, NAG, 
NAE, MAG, DAG, TAG, cholesterol, and cholesterol esters) tested.  Likewise, the TLC 
method outlined could be employed for qualitative composition studies. 
 Gas chromatography has been used to identify PFAMs isolated from luteal phase 
plasma2, N18TG2 mouse neuroblastoma cells
20,89, oleamide in plasma and cerebral spinal 
fluid21, and erucamide in pig organs and blood87.  All of the listed analyses employed a 
5HP-MS capillary column for separation.  The temperature elution profile differed 
slightly if the sample was trimethylsilyl derivatized or analyzed as the native structure.  
An alternative column, BPX-70, was able to resolve 6 C18:1 PFAM trimethylsilyl 
stereoisomers89.  The trans isomers eluted at least a minute prior to their corresponding 
cis isomers.  Additionally, the retention time was found to increase as the double bond 
position was closer to the carbonyl group.  The elution trends observed could aide in 
identification of stereoisomers even if mass spectrometry detection is not available. 
 Liquid chromatography is a viable alternative to gas chromatography, especially 
with the recent increases in column technology.  Reversed phase C18 stationary phases 
are the most common choice for separation of PFAMs20,25,55.  However, if resolution of 
short chain amides (C2-C12) are desired a C8 column can be employed25.  Separation is 
typically achieved by gradient elution with acetonitrile/water or methanol/water solvent 
mixtures.  Gradient elution programs vary depending on the resolution of analytes 
desired, the column properties and experimental details are provided in the cited 
publications.  These methods were used to purify erucamide from biological samples87, 
PFAM content in tallow90, and to examine PFAM content and anabolism in N18TG2 
mouse neuroblastoma cells20. 
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 For separation of NAEs and NAGs, Burstein et al. employed silica gel TLC of 
radiolabeled NAE and NAG substrates35.  Separation was achieved by a chloroform, 
methanol, acetic acid mixture and retention visualization was accomplished by 
scintillation counting.  Separation of NAGs from complex mixtures has been 
accomplished by primarily C18 reversed phase chromatography with water and 
acetonitrile or methanol gradients34,57,91.  Tissue studies were carried out in rat tissue and 
bovine brain34,57.    
 
1.4.2. Detection Methods 
 UV-Visible spectroscopy and mass spectroscopy (MS) detection methods were 
utilized in conjunction with the above separations.  Carpenter et al. used liquid 
chromatography with UV detection at 210 nm to assess PAM mediated changes in PFAM 
levels of mouse neuroblastoma cells25.  Because PFAMs do not absorb UV light readily, 
the limit of detection (100 µM) for this method was relatively high.  At this limit of 
detection, trace analysis is not possible unless a large amount of sample is processed and 
concentrated.  However, this method is useful, as an LC with a UV-Vis detector is 
ubiquitous in most institutions.  Other analysis systems for PFAM detection typically use 
a mass spectrometer because it is compatible with gas or liquid chromatography.  
Additionally, modes such as selected ion monitoring, or multiple reaction monitoring 
(MRM) in tandem mass spectrometers, can allow for lower detection limits, enabling 
trace analysis92.  When using electron ionization, as found in gas chromatography 
instruments, the fragmentation pattern can be matched to standard databases for 
component identification.  If PFAM fragmentation patterns are not provided in the 
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database software, reports have been published of electron ionization fragmentation 
assignment of PFAM-TMS derivatives93 or post-column mass spectra of collision 
induced dissociation of PFAMs94.  PFAM content in tallow was investigated by liquid 
chromatography atmospheric pressure chemical ionization mass spectrometry with a 
reported limit of detection of 18.5 femtomoles90. 
 Detection methods for NAGs have primarily been published on MS or tandem 
MS.  For quantitation studies of bovine brain and rat tissue LC/MS and calibration curves 
were used to determine levels of NAGs34.  This study ranged from value of 
approximately 2 to 140 pmol per gram of dry tissue.  Rimmerman et al. obtained 
quantitation of palmitoylglycine and N-arachidonoylglycine in Sprague-Dawley rat brain 
utilizing LC and tandem MS with a triple quadrupole operated in MRM mode57. 
Quantitation levels were between 6 and 895 pmol per gram of tissue.  Both reports 
demonstrate identification of NAGs in mixtures using accurate mass quadrupole time of 
flight mass spectrometers34,57.   
 
1.5. SUMMARY AND OUTLOOK 
 The knowledge gained on the metabolism and physiological interaction of 
PFAMs and biological systems has grown significantly since these molecules were first 
reported in 1989.  The degradation of these lipid messengers by FAAH is well 
characterized, however there are still ample questions pertaining to their anabolism in 
vivo.  The enzymes responsible for conversion of the fatty-CoA to the primary amide are 
still largely debated.  Additionally, there is still not a clear picture of how these molecules 
are regulated in signaling, whether systemically or locally within specific tissue regions.  
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Intraperitoneal injection of oleamide in mice causes a sleep-like state characterized by 
hypomotility, hypothermia, and ptosis that are not blocked by treatment with a CB1 
antagonist95.  Therefore, oleamide seems to exert physiological signaling effects that are 
independent of anandamide and the cannabinoid system.  Exogenous application of 
oleamide to the serotonin and GABA receptor systems indicated that physiological 
effects may be modulated by receptor interaction as deletion of the β3 subunit of the 
GABA receptor abolished the hypnotic effects observed with oleamide treatment11.  
Interestingly, differential phosphorylation was observed in the cellular connexin protein 
with exogenous application of oleamide in gap junction studies67. Therefore, PFAMs may 
modulate receptor function via downstream signaling or by changing phosphorylation 
states, although no further studies have been conducted.  Nonetheless, PFAMs are an 
emerging class of bioactive signaling molecules whose wide range of modulatory 
activities are only recently becoming discovered.  It is critical that the anabolic and 
signaling pathways for these physiologically-important effectors be elucidated.  This 
knowledge may provide invaluable insight to disease states or provide pharmacological 
strategies and novel therapeutics for a wide-range of symptoms, such as in treatment of 
pain and inflammation44.   
There are established isolation procedures and relatively predictive elution 
profiles of this class of lipids due to their structural similarity with fatty acids.  Future 
analyses of these classes of lipids will benefit from the rise in sophistication of column 
and mass spectrometry technology.  UPLC and nano-HPLC are advantageous as they 
reduce band broadening and total analysis time, providing analysis that is fast and of 
increased sensitivity.  Chipcube LC systems are available with an option of trapping 
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columns, thus, having the potential to increase sample load while reducing a portion of 
the matrix contaminants which can cause ion suppression in MS.  Our laboratory, 
amongst others, is also currently investigating microfluidics and laser induced 
fluorescence platforms to aid in reducing sample requirements and increasing detection 
sensitivity.  Initial findings indicate detection limits below those achievable by MS 
(unpublished work).  PFAMs and NAGs, unfortunately, are not currently represented in 
LIPID Metabolites and Pathways Strategy (LIPID MAPS)96, and MetLIN databases.  
However, several select PFAMs and NAGs are available in the Human Metabolome 
Database (HMDB).  Current efforts to determine anabolic pathways, receptor-ligand 
interaction studies, and new quantitative analysis in biological samples leaves the field 
poised for advancement in broadening our knowledge of the effects of PFAMs in vivo.  
 
 
 
 
 
 
 
 
 
 
 
 
 31 
Chapter 2 
 
Electrospray Ionization and Collision Induced 
Dissociation Mass Spectrometry of Primary Fatty 
Acid Amides and N-acyl Glycines  
 
Adapted from:  Divito, E. B., A. P. Davic, et al. (2012). "Electrospray ionization and 
collision induced dissociation mass spectrometry of primary fatty acid amides." 
Analytical chemistry 84(5): 2388-2394. 
 
2.1. ABSTRACT  
 Primary fatty acid amides are a group of bioactive lipids that have been linked 
with a variety of biological processes such as sleep regulation and modulation of 
monoaminergic systems.  As novel forms of these molecules continue to be discovered, 
more emphasis will be placed on selective, trace detection.  Prior to this report, there was 
no published experimental determination of collision induced dissociation of PFAMs.  A 
select group of PFAM standards, 12 to 22 length carbon chains, were directly infused into 
an electrospray ionization source Quadrupole Time of Flight Mass Spectrometer.  All 
standards were monitored in positive mode using the [M+H]+ peak.  Mass Hunter 
Qualitative Analysis software was used to calculate empirical formulas of the product 
ions.  All PFAMs showed losses of 14 m/z indicative of an acyl chain, while the 
monounsaturated group displayed neutral losses corresponding to H2O and NH3.  The 
resulting spectra were used to propose fragmentation mechanisms.  Isotopically labeled 
PFAMs were used to validate the proposed mechanisms.  Patterns of saturated versus 
unsaturated standards were distinctive, allowing for simple differentiation.  This 
determination will allow for fast, qualitative identification of PFAMs.  Additionally, it 
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will provide a method development tool for selection of unique product ions when 
analyzed in multiple reaction monitoring mode. 
 
2.2 INTRODUCTION 
Primary fatty acid amides (PFAMs) are a subclass of fatty acyls containing a 
carboxamide head group and an acyl tail of varying carbon length and unsaturation.  This 
group of lipids contains endogenous biomolecules, many of whose exact physiological 
role has not been identified.  Although distinct metabolic pathways have yet to be 
elucidated for this class of biomolecules, they have been located in several specific 
tissues and biological fluids since the late 1980s.  The first reported discovery of PFAMs 
was of palmitamide (hexadecanoamide, denoted C16:0), oleamide (C18:19) and 
linoleamide (C18:29, 12) in luteal phase plasma.2  Oleamide and erucamide (C22:113) were 
subsequently identified in the cerebral spinal fluid of sleep-deprived cats.15,16    
Exogenous application of oleamide was shown to potentiate serotonin receptor subtypes 
1A, 2A, and 2C, as well as to potentiate the class A type of ɣ-aminobutyric acid receptor, 
GABAAR.
3-6,10  Oleamide has also been found to inhibit gap junction communication 
when exogenously applied to glial cells.67,70  This lipid was reported to induce various 
physiological properties such as vasorelaxation, increased food uptake, anti-anxiety, and 
analgesic-like properties.9,14,17,18,62  While less well characterized than oleamide, the 
physiological properties of other PFAMs have been reported.  For example, erucamide 
promotes angiogenesis and regulates water balance56,87, and linoleamide induces sleep 
and increases cytosolic calcium levels in renal tubular cells.72  These effects have been 
ascribed to the carboxamide head group since the free fatty acid form does not produce, 
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or greatly reduces, the observed effects.  There is also selectivity shown for the double 
bond position and acyl chain length.  
PFAMs exhibit a broad range of physiological effects and, therefore, may be 
bioindicators for disease states. However this lipid class is typically found at low 
concentrations.  Investigation of the levels of these amides in biological fluids and tissues 
suggests that physiological concentrations are in the nM range.2,16,20,21  This makes 
separation and detection of physiological levels of PFAMs challenging.  Much of the 
separation and detection work to date has been conducted on the N-acylethanolamine, 
anandamide, though a few reports exist on other PFAMs.  Separation of PFAMs has 
involved mainly gas chromatography (GC) and high performance liquid chromatography 
(HPLC) with either the endogenous species or a derivatized form as the analyte.  PFAMs 
were analyzed in plasma2,  cerebral spinal fluid15, and mouse neuroblastoma cells20,89 by 
derivatization to trimethylsilylamides, followed by GC separation with mass 
spectrometry (MS).  HPLC is an alternative to GC for separation of PFAMs since it does 
not require derivatization if a MS detector is used.  HPLC-MS has been used to 
investigate the conversion of N-acylglycines to PFAMs in vitro25.   
In order to examine the presence and levels of PFAMs in biological samples it is 
necessary to first extract these lipids from the sample.  Folch-Pi or Bligh-Dryer extraction 
techniques are common; however these methods may co-extract other subclasses of fatty 
acyls such as fatty acids, N-acylethanolamines, and N-acylglycines.89  In addition, many 
of the fatty acyls are isobaric, further complicating the analyses.  This makes front-end 
separation a necessity as many of the isobars can be resolved solely by chromatography.  
Additionally, tandem MS is becoming a prevalent tool for selective, sensitive detection of 
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lipids.  The sensitivity has been reported as femtomoles in optimized systems.97,98  
Additionally, no sample derivativation is needed in an LC-MSMS system, making it 
attractive for lipid analysis. 
  Some fatty amide fragmentation mechanisms have been investigated with 
electron ionization or collision induced dissociation.93,99  There are a few reports on 
endogenous PFAMs where tandem MS was utilized for structural identification.15,100,101  
In order to enhance the selectivity and sensitivity of tandem MS using multiple reaction 
monitoring (MRM), knowledge of the fragmentation mechanism must be known.  This is 
especially true when investigating the fatty acyl group as all of the subclasses will contain 
acyl chain fragments in CID spectra.  It is, therefore, important to identify product ions 
that are unique to the fatty acyl subclass so that the selectivity and sensitivity of MRM 
can be utilized.  In order to provide essential tools to allow for identification of these 
physiologically relevant class of lipids, we report proposed fragmentation mechanisms of 
various saturated and mono-unsaturated PFAMs based on the observed product ions 
obtained with a quadrupole time of flight (QToF) MS. 
 
2.3. MATERIALS AND METHODS 
2.3.1 Chemicals:  
Methanol optima grade and ammonium hydroxide were purchased from Fisher 
Scientific (Fair Lawn, NJ, USA).  Oxalyl chloride, 13C2-9,10-oleic acid, oleic acid, erucic 
acid, petroselaidic acid, and anhydrous dichloromethane were from Sigma Aldrich (St 
Louis, MO, USA).  N, N-dimethylformamide, 13C-1-hexadecanoic acid, heptadecanoic 
acid, and eicosanoic acid were purchased from Aldrich Chemical Company (Milwaukee, 
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WI, USA).  Lauric acid, myristic acid, palmitic acid, stearic acid, formic acid, and 
docosanoic acid were purchased from Acros Organics (New Jersey, USA).  Elaidic acid 
was from MP Biomedical Inc. (Solon, OH, USA) and linoleamide was purchased from 
Enzo Life Sciences (Ann Arbor, MI, USA).  Oleoylglycine was purchased from Cayman 
Chemicals (Ann Arbor, MI, USA). 
 
2.3.2 PFAM synthesis:  
PFAMs were synthesized by a modified procedure described by Philbrook.102  
Fatty acids were dissolved in anhydrous dichloromethane and converted to the acid 
chloride by reaction with oxalyl chloride under anhydrous argon atmosphere. 
Dichloromethane solvent was removed by rotary evaporation in vacuo, and the remaining 
acid chloride was subjected to ammonia gas by insertion of ammonium hydroxide filled 
syringes.  Reactions were complete when the fatty acid chloride oil was completely 
converted to a white solid fatty acid amide product.  Products were purified by liquid 
phase extraction with chloroform. 
Purity of all synthesized amides was verified by GCMS on a Varian CP-3800 GC 
with Varian Saturn 2000 Ion Trap Mass Spectrometer.  Gas chromatography was 
performed on a Varian Factor Four Capillary Column (VF-5ms, 30 m × 0.25 mm ID) 
with a flow of 1 mL/min helium carrier gas.  Injector temperature was held at 250oC with 
split injection (ratio 10).   Temperature gradient started at 55oC and ramped 40oC/min to 
150oC with a hold of 3.62 minutes before ramping 10oC/min to 275oC and holding 6.50 
minutes.  The total run time was 25 minutes.  Eluted fatty amides were ionized by 
chemical ionization with methanol and analyzed in selected ion mode.  The peak area of 
 36 
fatty acid substrate and PFAM product from GC-MS runs were used to determine purity.  
All PFAMs were found to be of 98% purity or greater. 
 
2.3.3 Mass spectrometry: 
PFAM fragmentation patterns were obtained on an Agilent Technologies 6530 
Accurate Mass QToF LCMS with electrospray ionization source.  Samples of 10 µM of 
amide in 95:5 methanol/water solvent with 0.3% formic acid (v/v) were introduced by 
direct infusion at 500 µL/min using a Harvard Apparatus 11 Plus syringe pump.  Mass 
spectral parameters were as follows:  gas temperature 300oC, drying gas 8 L, nebulizer 
pressure 35 psi, sheath gas temperature 350oC, sheath gas flow 11 L, capillary voltage 
4000 V, fragmentor voltage 150 V, nitrogen collision gas, and collision energy 20-35 mV 
depending on sample identity.  Each sample was infused and spectra collected for 1 
minute, with a final average of 20 scans/spectra.   Empirical formulas for product ions 
were generated using Mass Hunter Workstation Software Qualitative Analysis.  
   
2.4. RESULTS 
In order to understand the mechanism of PFAM CID a select group containing 
lauramide (C12:0), myristamide (C14:0), palmitamide (C16:0), oleamide (C18:19), 
elaidamide (C18:19t), petroselaidamide (C18:16t), stearamide (C18:0), arachidamide 
(C20:0), erucamide (C22:113), and behenamide (C22:0) were directly infused into an 
electrospray ionization source coupled to a QToF.  N-acyl glycine (NAG) fragmentation 
patterns were obtained via direct infusion into an electrospray ionization source, operated 
in negative mode, coupled to a triple quadrupole mass spectrometer. All PFAM parent 
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ions were observed as the [M + H]+ ion and NAGs as the [M - H]-.  Fragmentation 
patterns for both classes of fatty acyls were obtained at collision energies from 20 -100 V 
(Figure 2-1).  As the collision energy increased the patterns were dominated by the 
occurrence of smaller product ions. Empirical formula generation suggested that the 
fragmentation pathways for all saturated PFAMs were similar regardless of the acyl chain 
length.  All MS/MS spectra contained an acyl chain fragment observed at 57 m/z (Figure 
2-2).  Additionally, several fragment ions were identified by isotope ratio analysis to 
contain both nitrogen and oxygen.  This is observable in both the parent ion mass and 
isotope distribution.  The parent ion mass is an odd number value (if the additional proton 
charge is removed) which is attributed to the single nitrogen atom present in the structure.  
The major parent ion peak is comprised of the most stable atomic isotopes.  Peaks of 
greater mass in the ion cluster are compounds containing the lesser abundant isotopes.  In 
these examples a peak at 2 m/z greater than the parent ion is due to the 0.204% 
probability of the compound containing 18O.  In this way isotope ratio analysis was used 
to determine the empirical formulas for each major product ion.  The product ions were 
interpreted to be fragments which contain the head group carboxamide but differ by the 
acyl chain fragmentation point.  As the acyl tail length was increased, the occurrence of 
higher mass product ions increased, and differed by 14 m/z.  This supported the 
hypothesis that the acyl chain fragmentation point was variable.  An isotopically labeled 
palmitamide (13C-1-hexadecanoamide) was used to confirm the identity of the proposed 
head group fragments.  In this case the product ions containing the head group carbon 
would be mass shifted by 1 amu (Figure 2-3A), while the acyl chain fragment at 57 m/z 
would remain unchanged.  These suspected product ion assignments were used to 
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propose a fragmentation mechanism for the saturated PFAMs.  The head group fragments 
form by β-hydrogen rearrangement causing the product ion to terminate with a methyl, 
while the remainder of the acyl tail was lost as a neutral fragment (Figure 2-3B).  An 
alternate fragmentation mechanism to that proposed is homolytic cleavage of the carbon-
carbon bond with radical hydrogen transfer, as described by Wysocki and Ross.103  This 
type of fragmentation was most common at carbons 3-6 from the carboxamide moiety 
(for collision energies of 20-35 V), producing the largest observed alkyl loss.  The acyl 
chain fragment was proposed to form through bond rearrangement to produce a singly 
charged acyl fragment.  The secondary product then undergoes a hydrogen rearrangement 
from the carboxamide ion to the alkene tail resulting in a neutral loss (Figure 2-3C).  This 
was supported by product ion peaks, as no doubly charged head group fragment was 
observed.  An alternative fragmentation mechanism for acyl tail formation could involve 
β-hydrogen rearrangement within the acyl tail, and a bond rearrangement at a position of 
4 or less carbons away. This type of fragmentation would produce a neutral loss of an 
alkene chain, an acyl chain fragment of 57 m/z or less, and a doubly charged 
carboxamide fragment that would undergo hydrogen rearrangement previously described, 
to result in another neutral loss. Both acyl chain fragmentation pathways are probable, as 
product ions of 43 and 29 m/z can be observed on MS with mass scanning capabilities 
below 50 m/z (data not shown). 
 Monounsaturated PFAMs had a distinct fragmentation pattern when compared 
with saturated PFAMs (Figure 2-4).  The major difference was the loss of 17 and 35 m/z 
indicating the loss ammonia, and both ammonia and water from the carboxamide.  These 
losses were verified by empirical formula analysis, and have been previously reported.15  
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The remaining product ions were identified as alkyl chains of varying length, as well as 
the acyl fragment of 57 m/z that was observed in the saturated PFAM fragmentation 
patterns.  Because all the product ions were identified as alkyl chains, it was postulated 
that the loss of water and ammonia was a fast process resulting in a positively charged 
alkyl fragment of m/z 247 (Figure 2-5A).  The loss of ammonia and water gave rise to 
product ions 265 and 247 m/z.  These ions have been observed in similar CID 
experiments conducted on phosphotidylcholines.104 This 247 m/z alkyl carbocation would 
then fragment and give rise to the remaining product ions observed. Changing the length 
of the acyl chain or the position/stereochemistry of the double bond did not alter the 
observed product ion masses.  This could be explained by hydrogen rearrangement 
causing double bond labiality, as depicted in Figure 4B.  The product ions observed at 83 
and 69 m/z arise from charge directed fragmentation of the 247 m/z alkyl carbocation, as 
depicted in Figure 4C.  An isotopically labeled oleamide (13C2-9, 10-octadecanoamide) 
fragmentation pattern was examined to determine bond cleavage points (Figure 2-5).  135 
m/z product ion was calculated to have an empirical formula of C10H15 and to contain 
both isotope labels.  This suggests that the fragmentation point was just to the left of the 
double bond position.  Likewise, 121 m/z empirical formula was C9H13 and contained just 
one 13C label, indicating a cleavage at the double bond position.  This result confirmed 
the proposed mechanism shown in Figure 2-4B.  The product ions observed at 83 and 69 
m/z were not mass shifted due to 13C labeling, confirming the proposed charge directed 
fragmentation mechanism (Figure 2-4C). 
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Figure 2-1.  CID of 10 µM standards of A: stearamide, B: 
oleamide, and C: oleoylglycine directly infused at 0.50 
mL/minute using a Harvard A11 syringe pump into a 
Agilent 6460 triple quadrupole.  The collision energy was 
varied and is depicted in the legend of each figure. 
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Figure 2-2.  Product ion scans of saturated PFAMs from CID-MS.  A: Lauramide (C12:0), 
B: myristamide (C14:0), C: palmitamide (C16:0), D: stearamide (C18:0), E: arachidamide 
(C20:0), and F: behenamide (C22:0).  All samples were approximately 10 µM and were 
directly infused into an ESI-QToF at a rate of 500 µL/min.  Collision energy was set to 20 
V for each sample except behenamide (C22:0) which was collected at 35 V. 
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Figure 2-3.  A: Product ion scans of palmitamide (black) and 13C-1-palmitamide (red). 
All samples were approximately 10 µM and were directly infused into an ESI-QToF at 
a rate of 500 µL/min with a collision energy of 20 V.  The top trace is offset on the y-
axis by 100 units.  B: Proposed β-hydrogen rearrangement resulting in the head group 
containing fragments.  The * denotes the position of 13C in case of isotopically labeled 
analyte.  C: Proposed bond fragmentation to yield a 57 m/z product ion. 
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Figure 2-4.  Product ion scans of monounsaturated PFAMs from collision induced 
dissociation MS at a CE of 20 V.  A: oleamide (C18:19), B: elaidamide (C18:19t), C: 
petroselaidamide (C18:16t), and D: erucamide (C22:113).  All samples were approximately 
10 µM and were directly infused into an ESI-QToF at a rate of 500 µL/min. 
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Figure 2-5.  A: Proposed mechanism for the loss of ammonia and water from 
PFAMs.  B: Hydrogen rearrangement resulting in double bond movement and 
fragmentation to yield the observed alkyl product ions.  C:  Charge directed 
fragmentation resulting in product ion 69 m/z and a neutral loss. 
 
Figure 2-6.  Product ion scans of oleamide (bottom trace) and 13C2-9, 10-oleamide (top 
trace).  All samples were approximately 10 µM and were directly infused into an ESI-
QToF at a rate of 500 µL/min.  Both spectra were collected at 20 V collision energy.  
The top trace is offset on the y-axis by 100 units.  The most abundant peak in the ion 
cluster was mass labeled.   
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The group of product ions between 105 and 118 m/z was scrutinized because of the 
differences in relative intensity between isobars.  In a double blind test the change in 
relative intensity between the product ions in the group, though not significant, was 
enough to obscure accurate identification (data not shown).   
 Oleoylglycine fragmentation pattern (Figure 2-7) has an [M – H]- parent ion and 
displayed major product ions of 294 and 74 m/z.  Upon inspection of the molecular 
structure the product ion 74 m/z was proposed as the deprotoned form of the glycine head 
group.  The remaining product ion revealed a similar fragment loss of 57 m/z that was 
observed in the saturated PFAM CID (Figure 2-2).  This ion was not observed in the 
oleoylglycine spectra as the 57 m/z occurs as the positive ion. 
 
2.5. DISCUSSION AND CONCLUSION  
CID patterns of saturated and monounsaturated PFAMs, ranging in acyl chain 
length from 12 to 22, were collected and analyzed to determine the empirical formulas of 
the product ions.  The saturated PFAMs were found to contain similar product ion peaks 
Figure 2-7.  CID pattern of 10 µM oleoylglycine standard directly infused at 0.50 
mL/minute using a Harvard A11 syringe pump into a Agilent 6460 triple quadrupole 
equipped with an ESI source operated in negative mode.  The parent ion was observed as 
the [M – H]-.  The most abundant peak in the ion cluster was mass labeled.  The molecular 
structure shows the proposed bond fragmentation site. 
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containing carbon, oxygen, hydrogen, and nitrogen except for the product ion 57 m/z, 
which contain carbon and hydrogen.  Product ion peaks containing nitrogen and oxygen 
were proposed to be fragments including the carboxamide head group and differing in the 
acyl fragmentation site.  The 57 m/z product ion, present in both the saturated and 
monounsaturated PFAMs, was identified as an acyl chain fragment.  The fragmentation 
patterns observed for saturated PFAMs are similar to patterns observed for fatty acids 
analyzed in positive mode as lithium adduct ions.103,105  Both display product ions 
separated by 14 m/z units which is characteristic of acyl chain lipids.   Additionally, bond 
fragmentation within the acyl chain occurs by similar charge remote fragmentation 
mechanisms.103,106,107  One distinct difference between fatty acid and PFAM 
fragmentation is the charged fragment does not terminate in an alkene in the latter case.  
This change can either occur directly by β-hydrogen rearrangement before alkane bond 
cleavage or by radical hydrogen attachment after a homolytic bond fragmentation (Figure 
2-2B).  The product ions observed do not support the typical pericyclic 1,4 hydrogen 
elimination mechanism reported for fatty acid CID.  Additionally, at the collision energy 
tested, no loss of water or ammonium was observed from the carboxamide of saturated 
PFAMs, as is sometimes seen in fatty acid or fatty amide CID.103,108,109 
The defining characteristic of the monounsaturated PFAM fragmentation patterns 
was the [M + H -17] and the [M + H – 35] product ion peaks, indicating the loss of 
ammonia and water from the carboxamide head group.  These two product ion peaks, as 
well as the acyl tail signature, can be diagnostic of PFAMs when observed in typical 
biological systems.  The remaining fragments were identified as alkyl chain fragments.  
Increasing chain length increased the appearance of higher mass product ions when 
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exposed to constant collision energy. The product ions are expected to be terminal 
alkenes, however observed masses do not support a pericyclic fragmentation mechanism.  
A change in the position or stereochemistry of the double bond did not change the 
product ions observed, consistent with previously reports of unsaturated fatty acids.110  
For this reason, the identity of isobaric compounds could not be differentiated.  
Therefore, if isomer identification by MS alone is necessary, the double bond should first 
be derivatized to prevent labiality110 or a front end LC method capable of separating 
isobars must be developed. 
In contrast to the PFAMs, NAGs occur as [M – H]- parent ions.  The major ions 
observed in the oleoylglycine fragmentation pattern 294 and 74 m/z.  These ions were 
proposed to be the deprotonated form of glycine at 74 m/z.  Product ion 294 m/z exhibited 
a loss of 57 m/z and was proposed to lose this fragment via hydrogen rearrangement 
similar to the mechanism proposed for saturated PFAMs.  No charge rearrangement 
occurs in this case and the positive 57 m/z ion is not observed in negative ion mode.      
The important role of lipids in biology and health, as well as the emergence of 
sensitive detection platforms utilizing mass spectrometry, have driven the field of 
lipidomics (recently reviewed in a special Chemical Review issue on “Lipid 
Biochemistry, Metabolism, and Signaling”).111  Despite the physiological significance of 
PFAMs2-18 (see Chapter 1: Metabolism, Physiology, and Analyses of Primary Fatty 
Acid Amides) , this class of lipids have not been extensively characterized and is not 
well represented in the LIPID Metabolites and Pathways Strategy (LIPID MAPS) 
consortium site (www.lipidmap.org).112  In this work we have reported CID patterns for 
various saturated and monounsaturated PFAMs and successfully employed isotope 
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labeled compounds to elucidate fragmentation mechanisms, providing essential 
information necessary for further analytical studies on this class of lipids. 
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Chapter 3 
Chromatographic Separation Methods for Fatty Acyls 
3.1. ABSTRACT 
 The view of lipids in biochemistry is expanding as numerous fatty acyls are 
discovered to possess signaling properties.  These signaling lipids are often found in 
quantities of pmol/g of tissue and are co-extracted with numerous lipophilic molecules, 
making their detection and identification challenging.  Common analytical means involve 
chromatographic separation and MS techniques; however, a single step is typically 
inefficient due to the complexity of the sample.  It is, therefore, essential to develop 
approaches that incorporate multiple dimensions of separation.  Described in this chapter 
are normal phase, reversed phase, and silver ion separation strategies for fatty acyls that 
included tandem MS as a detection method and additional means of separation and 
identification.  These approaches are intended to be used in concert to accommodate 
quantitation of highly complex samples. 
 
3.2. INTRODUCTION 
 Lipids are typically viewed in terms of constituents of cellular membranes and 
modes of energy storage; however, many lipids exert bioactive properties through cellular 
signaling means.  NAEs have a long history of physiological and G-protien receptor 
mediated effects that are directly related to, or reminiscent of, cannabinoid activation113-
116.  PFAMs and NAGs, however, are just beginning to be recognized as bioactive 
signaling lipids that have demonstrated interactions with serotonin receptors4-7, gap 
junction proteins and calcium signaling57,67,70-72, and a myriad of physiological 
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effects11,15,17,19,52-54,56,117-119 (see Chapter 1: Metabolism, Physiology, and Analyses of 
Primary Fatty Acid Amides) .  Of these documented effects, the most potent bioactive 
lipids consist of 16-22 chain length acyl tails and can be saturated or unsaturated species.  
In addition, it is hypothesized that aberrant endogenous levels of these species, either by 
down-stream modulation or alteration of their metabolic enzymes, could contribute to 
disease states.  This is an intriguing consideration as PFAMs are known to have high 
affinity for serotonin receptors, though no reports exist for PFAM levels in this disease 
phenotype.  Evidence for up-regulation of NAEs exists in studies of chronic pain120, 
schizophrenia121, depression and anxiety122, yet the physiological relevance of these 
observations is still unclear.  In light of this, it is of substantial importance to develop 
analysis strategies for bioactive fatty acyls.  These methods, in combination with 
phenotype studies, will aid in the elucidation of the role of signaling lipids and disease 
states.  The generated methodologies may provide additional tools for diagnosis and 
development of treatment strategies.   
Lipid milieus of biological samples are often very complex mixtures.  Even the 
most common lipid extraction methods, such as Folch-Pi86, remove a mélange  of several 
different lipid classes.  Identification of isomers and isobars by standard separation 
methods, such as normal phase and reversed phase chromatography, is often insufficient 
for complete identification of all constituents.  Silver ion chromatography has been used 
extensively for separation of lipid samples with a high variation of unsaturation numbers 
of geometrical configuration123-134.  However, silver ion separations cannot differentiate 
between trans-unsaturated and saturated analytes.  
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Multidimensional liquid chromatography (MDLC) analysis is the process of 
injecting samples onto a liquid chromatography system where two different separation 
schemes (columns or dimensions) are used135-139. The main advantage of MDLC is the 
dramatic increase in peak capacity known as the “product rule”; where the maximum 
peak capacity becomes the product of the two individual chromatographic peak 
capacities.  These different separation schemes must be orthogonal, or operate by 
different separation mechanisms, in order to achieve maximum capacity.  Analysis by 
two different chromatographic dimensions allows for the separation of difficult to resolve 
components or samples with a high number of constituents.  
There are several terms for describing multidimensional systems. The first is a 
distinction between online and off-line systems. An on-line system uses a switching valve 
to divert fractions of the 1st dimension flow directly to the 2nd dimension. Off-line 
systems use two different chromatography steps where the sample is collected from the 
first dimension, dried down and reconstituted for injection into a second system.  
For online MDLC the 2nd dimension separation must be very fast so that extreme 
band broadening due to longitudinal diffusion is minimal in the 1st dimension. One option 
for shorter analysis times is the use of columns with particle sizes smaller than 3 μm. The 
reduction in particle sizes results in a decrease in the resistance to mass transfer between 
the two phases. This allows the analysis to be run at an increased linear velocity, thereby, 
reducing the analysis time. Additionally, the plate height is decreased as the square of the 
particle size according to the van Deemter relationship140-142. Since plate height is 
inversely related to peak resolution, this produces a more efficient separation between 
analytes. 
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Additionally, the switching valve timing, the amount of time between loop 
switching (process that diverts small eluent fractions from the 1st dimension to the 2nd 
dimension for analysis), and loop size must be determined after successful method 
development of both dimensions.  Both methods have the advantage that if separation 
mechanisms between dimensions are orthogonal then maximum peak capacity is 
achieved. Off-line systems are advantageous because there is no concern of sample 
solvent miscibility between separation dimensions. However, the analysis time is 
generally longer because samples have to be processed between separations.  
Silver ion chromatography is a method for separating molecules with different 
degrees of unsaturation.  The general mechanism of action in this separation scheme is 
unclear, though, Christie and co-workers propose a theory of silver ions forming weak, 
reversible charge transfer complexes with the analytes128,143-145.  Another possibility is an 
intermolecular ion-dipole interaction between the loaded silver ions on the 
chromatographic bed and the π bonds of the analyte.  In general, elution order of analytes 
by this technique is saturated, trans-unsaturated, mono-unsaturated, and so on.  A number 
of experimental parameters and analyte variables have been explored in relation to 
retention factor allowing implementation of this methodology in a predictable 
manner127,146,147.  One exception to typical chromatographic separations is that retention 
of analytes in silver ion chromatography is reduced at lower temperature148.   
Both online and offline MDLC separations have been demonstrated for TAGs in 
plant and animal samples131-134.  Each approach utilized a reversed phase separation with 
an isopropanol/acetonitrile gradient and an isocratic silver ion separation with 0.5-0.7% 
acetonitrile in hexane.  Samples that were separated with an online MDLC approach 
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always had a reversed phase 2nd dimension separation with a total analysis time of less 
than 2 minutes131,133.  MDLC has not yet been demonstrated with PFAMs and NAGs, 
although or laboratory has utilized an SPE method prior to GC-MS analysis149.  The 
following sections demonstrate various separation methods for PFAMs, NAGs, and fatty 
acid phenacyl esters.  We additionally propose an offline separation method for future 
utilization.      
  
3.3. MATERIALS AND METHODS 
3.3.1 Chemicals 
Methanol optima grade, formic acid optima grade, ammonium acetate, silver 
nitrate, hexane, dichloromethane, acetonitrile, and ammonium hydroxide were purchased 
from Fisher Scientific (Fair Lawn, NJ, USA).  Oxalyl chloride, oleic acid, erucic acid, 
petroselaidic acid, heptane HPLC grade, methyl-tert-butyl-ether HPLC grade, 
isopropanol HPLC grade, acetic acid, and anhydrous dichloromethane were from Sigma 
Aldrich (St Louis, MO, USA).  N, N-dimethylformamide, heptadecanoic acid, and 
eicosanoic acid were purchased from Aldrich Chemical Company (Milwaukee, WI, 
USA).  Lauric acid, myristic acid, palmitic acid, stearic acid, and docosanoic acid were 
purchased from Acros Organics (New Jersey, USA).  Elaidic acid was from MP 
Biomedical Inc. (Solon, OH, USA) and linoleamide was purchased from Enzo Life 
Sciences (Ann Arbor, MI, USA).  Oleoylglycine, Linoleoylglycine, palmitoylglycine, 
arachidonoylglycine, and arachidoylglycine were purchased from Cayman Chemicals 
(Ann Arbor, MI, USA). 
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3.3.2 Normal Phase Separation 
 PFAM and NAG standards were prepared in a mixture at 1 mM concentration of 
each standard.  The mixture was separated via normal phase chromatography utilizing a 
YMC PVA-Sil column (4.6 × 250 mm, 5 µm particle size).  Gradient elution is carried 
out starting at 95 % mobile phase A (heptane with 0.5% v/v methyl-tert-butyl-ether) and 
increasing linearly to 50% mobile phase B (methyl-tert-butyl-ether with 10% v/v 2-
propanol and 0.2% v/v acetic acid) over 40 minutes with a flow rate of 1 mL/minute 
(gradient developed by Kroniser and Johnson, unpublished).  Fractions were collected at 
one minute intervals and the times corresponding to NAG and PFAM elution are 
determined by reversed phase chromatography and MS/MS detection. 
 
3.3.3 Silver Ion Chromatography 
 Select saturated, monounsaturated, and di-unsaturated fatty acids were derivatized 
to fatty acid phenacyl esters (FAPEs) by reaction of excess 2-bromoacetophenone and a 
triethylamine catalyst in an acetone solvent carried out in sealed culture tubes that were 
placed in a boiling water bath for approximately 45 minutes150.  After 45 minutes the 
reaction was cooled to room temperature and then an acetic acid solution was used to 
convert any unused 2-bromoacetophenone reagent to phenacyl acetate.  Prior to 
separation the reaction solution was dried under nitrogen and reconstituted in hexane.   
 The silver ion column was prepared from a Waters Spherisorb SCX column (4.6 
× 150 mm, 5 µm particle size) by injection of 20 µL aliquots of 10% aqueous silver 
nitrate solution to a total volume of 1 mL.  After the silver ions were loaded onto the 
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cation exchange column, the system was flushed for one hour, and then stored in a 
hexane solvent.   
 10 μM FAPE samples were analyzed on the prepared silver-ion column connected 
to a Waters 600 HPLC system equipped with a Waters 2487 Dual λ Absorbance Detector 
operated at a wavelength of 250 nm.  A 20 μL loop was used for sample loading and 
elution was achieved using a solution of 59.7/39.8/0.5   
hexane/dichloromethane/acetonitrile in isocratic mode with a flow rate of 1 mL/minute.  
  
3.3.4 Reversed Phase Separation of N-acyl Glycines 
 Palmitoylglycine, linoleoylglycine, oleoylglycine, stearidonoylglycine, 
arachidonoylglycine, and arachidoylglycine were analyzed on an Agilent Technologies 
1200 Liquid Chromatography system with a 6460 Triple Quadrupole Mass Spectrometry 
Detector.   Mobile phase A was methanol and mobile phase B water both contained 10 
mM ammonium acetate.  Separations were carried out on a YMC Cartenoid column (4.6 
× 150 mm, 5 µm particle size) with a linear gradient of 90% to 100% mobile phase A 
over 15 minutes with a 15 minute hold time.  An additional separation method was 
developed on a Phenomenex C18 column (4.6 × 100 mm, 2.6 µm particle size) with a 
linear gradient of 80% to 100% mobile phase A over 5 minutes and a 2 minute hold time.  
A second gradient method was used and consisted of 70% mobile phase A hold for 7 
minutes, a linear gradient increase to 80% for 7 minutes, a 1 minute hold at 80% before 
increasing to 100% mobile phase A over 5 minutes, and a final 5 minute hold for a total 
analysis time of 25 minutes. 
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 Ionization was achieved with an ESI source operated in negative mode with 
optimized parameters: fragmentor voltage 135 V, sheath gas flow 11 L/minute, nebulizer 
pressure 55 psi, nozzle voltage 500 V, capillary voltage 3500 V, drying gas flow 9 
L/minute, drying gas temperature 275oC, and dwell time of 500 ms.  Multiple reaction 
monitoring parameters were set-up to analyze the [M – H]- parent ions and 74 m/z 
product ion. 
3.3.5 Reversed Phase Separation of Primary Fatty Acid Amides 
 All primary fatty acid amide standards were synthesized in house at greater than 
98% purity (Chapter 2 Section 3.2 PFAM synthesis).  Lauramide (C12:0), myristamide 
(C14:0), linoleamide (C18:29, 12), palmitamide (C16:0), oleamide (C18:19), elaidamide 
(C18:19trans), petroselaidamide (C18:16trans), heptadecanoamide (C17:0), stearamide 
(C18:0), arachidamide (C20:0), erucamide (C22:113), and behenamide (C22:0) were 
separated on a Agilent RP C18 column (2.0 × 50 mm, 1.8 µm particle size) with a 
gradient elution of methanol, optima grade and water both containing 0.3% formic acid.   
 PFAMs were detected using an Agilent 6460 Triple Quadrupole Mass 
Spectrometer equipped with an atmospheric pressure chemical ionization (APCI) source.   
Optimized detection parameters are as follows:  gas temperature 325oC, vaporization 
temperature 325oC, gas flow 4 L/minute, nebulizer pressure 22 psi, capillary voltage 
3500 V, corona 4 µA, and fragmentor 125 V.  Multiple reaction monitoring was used to 
detected the [M + H]+ parent ions and product ions of 55 and 43 m/z for the 
monounsaturated and saturated compounds respectively. 
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3.4. RESULTS 
3.4.1 Normal Phase Separation 
 A 975 nmol lipid mixture of fatty acids (FA), triacylglycerols (TAG), 
diacylglycerols (DAG), monoacylglycerols (MAG), NAGs, PFAMs, and NAEs standards 
were separated by normal phase chromatography (Figure 3-1. Kroniser and Johnson, 
unpublished). 
 
 
Sample injection volume was increased from 20 µL to 200 µL to accommodate larger 
scale sample purification needs.  The effect of the increased injection volume on elution 
was tested by collecting one fraction per minute over the total analysis time.  These 
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Figure 3-1.  Chromatogram of seven fatty acyl subclasses separated by normal phase 
chromatography using  a YMC PVA-Sil (4.6 × 250 mm, 5 µm particle size) on a Waters ZMD MS 
with an ESI probe with polarity switching.  Separation was achieved with mobile phase A (heptane 
with 0.5 % methyl-tert-butyl ether) and mobile phase B (10% 2-propanol, 0.2% acetic acid in 
methyl-tert-butyl ether) run in gradient mode from 95% to 50% A over 40 minutes.  The 
monoacylglycerol (MAG) were monitored as the [M+Na]+ peak, PFAM as the [M+H]+ peak, DAG 
as  [M+Na]+ peak, NAE as [M+Na]+ peak, FA as [M-H]- peak, NAG as  [M-H]- peak, and TAG 
[M+Na]+ peak.   Each class was monitored on a different channel on the MS.   
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fractions were dried down, reconstituted in methanol, and analyzed by reversed phase 
methods (Figure 3-2).  The NAGs and PFAMs were found to co-elute from 31 to 38 
minutes (Figure 3-2B, C).  Co-elution was determined not to be problematic because 
these species ionize in different modes for reversed phase MRM analysis (see 3.4 
Reversed Phase Separation of N-acyl Glycines and 3.5 Reversed Phase Separation of 
Primary Fatty Acid Amides). 
 
 
 
Figure 3-2.  (A)Representative chromatogram of fractional PFAM elution from normal 
phase chromatography collected from 34-35 minutes.  Fraction was dried down, 
reconstituted in methanol and analyzed on an Agilent RP C18 (2.0 × 50 mm, 1.8 µm 
particle size) with methanol/water gradient elution.  0.3% formic acid was added as an 
ionization aid and multiple reaction monitoring was used.  (B) PFAM and (C) NAG 
standards eluted from the normal phase chromatography separation on a YMC PVA-Sil 
column (4.6 × 250 mm, 5µm particle size) with gradient elution (see 3.2 Normal Phase 
Separation for gradient information).   Fractions were collected each minute, dried and 
reconstituted in methanol.  Fractions were analyzed by reversed phase chromatography.  
All peaks observed in each fraction were summated and represented as the peak area per 
fraction. 
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3.4.2 Silver Ion Chromatography 
FAPEs were prepared from select fatty acids ranging in carbon chain length from 
12 to 22 and 0 to 2 degrees of unsaturation.  Successful derivatization was confirmed by 
UV-visible and FT-IR spectroscopy (data not shown).  Thin layer chromatography also 
confirmed synthesis of the FAPE from oleic acid by an Rf value of 0.406 which was in 
good agreement with literature reports129.  Addition of acetic acid to the FAPE reaction 
mixture after heating was necessary to prevent excess 2-bromoacetophenone from 
degrading the FAPE products.  A mixture of stearic, oleic, and linoleic acid phenacyl 
esters were prepared and separated on a strong cation exchange column loaded with 
silver ions (Figure 3-3A).  Elution order was determined by individual injection of each 
of the FAPEs.  An additional peak was present in each of the chromatograms that was 
due to excess phenacyl bromide reagent, therefore, the individual products and mixture 
was spiked with phenacyl bromide to confirm elution time.  Stearic acid phenacyl ester 
was found to elute first followed by excess phenacyl bromide, oleic acid phenacyl ester, 
and linoleic phenacyl ester. 
 The effect of chain length on separation was determined by injection of saturated 
FAPEs from 14 to 20 carbons as both individual FAPEs and as a mixture (Figure 3-3B).  
It was found that the saturated FAPEs co-eluted as one peak with the longer chain FAPEs 
eluting near the beginning of the mixture.  This co-elution trend did not continue with 
increasing degrees of unsaturation as distinct peaks were observed for oleic acid phenacyl 
ester and erucic acid phenacyl ester (Figure 3-4).  
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Figure 3-3.  (A) FAPE elution by silver ion chromatography with an isocratic mobile phase of 
59.7/39.8/0.5   hexane/dichloromethane/acetonitrile at a flow rate of 1 mL/minute and UV 
monitoring at 250 nm.  (1) Stearic acid phenacyl ester, (2) phenacyl bromide, (3) oleic acid 
phenacyl ester, (4) linoleic acid phenacyl ester.  The red trace is elution of the mixture of FAPEs 
and the black trace shows the mixture that was spiked with phenacyl bromide reagent.  Both 
traces were normalized to the intensity of (4) to account for absorbtion variability between runs. 
(B) Saturated FAPEs elution by silver ion chromatography with an isocratic mobile phase of 
59.7/39.8/0.5   hexane/dichloromethane/acetonitrile at a flow rate of 1 mL/minute and UV 
monitoring at 250 nm.  Elution order is as follows:  behenic acid phenacyl ester (C22:0, red), 
arachidic acid phenacyl ester (C20:0, orange), stearic acid phenacyl ester (C18:0, yellow), 
palmitic acid phenacyl ester (C16:0, green), myristic acid phenacyl ester (C14:0, blue).  The 
mixture of C14:0 to C22:0 is shown in black. 
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3.4.3 Reversed Phase Separation of N-acyl Glycines 
 Palmitoylglycine (C16:0), oleoylglycine (C18:19), linoleoylglycine (C18:29,12), 
stearidonoyolglyicne (C18:46,9,12,15), arachidonoylglycine (C20:45,8,11,14), and 
arachidoylglycine (C20:0) were separated utilizing a C30 YMC carotenoid column and a 
fused-core Phenomenex C18 column.   
 Separation of palmitoylglycine (C16:0), oleoylglycine (C18:19), linoleoylglycine 
(C18:29,12), and arachidoylglycine (C20:0) was achieved on a C30 YMC carotenoid 
column (4.6 × 150 mm, 5 µm particles size) with gradient elution of methanol and water.  
Both mobile phases were modified with 10 mM ammonium acetate to aid in ionization.  
Elution was achieved by linear increase in methanol from 90-100% over 15 minutes, 
followed by a 15 minute hold.  Elution of each component was determined by the parent 
mass (Figure 3-5A). 
 
 
Figure 3-4.  Elution of FAPEs by silver ion chromatography with an isocratic mobile 
phase of 59.7/39.8/0.5   hexane/dichloromethane/acetonitrile at a flow rate of 1 
mL/minute and UV monitoring at 250 nm.  (1) saturated FAPEs C14:0 to C22:0, (2) 
excess phenacyl bromide, (3) erucic acid phenacyl ester, (4) oleic acid phenacyl ester, 
(5) eicosadienoic acid phenacyl ester, (6) linoleic acid phenacyl ester. 
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In an effort to reduce the analysis time, a fused-core Phenomenex C18 column (4.6 × 100 
mm, 2.6 µm particles size) was employed using methanol/water gradient elution (Figure 
3-5B).  The use of a fused-core particle C18 column reduced the experimental time by 6 
fold compared to the C30 column separation while simultaneously increasing resolution.   
Figure 3-5.  Separation of NAGs on (A) a C30 YMC carotenoid column (4.6 × 150 mm, 5 um 
particles size) and (B, C) Phenomenex C18 column (4.6 × 100 mm, 2.6 µm particles size) using two 
different gradient separations.  Ionized by ESI and detected in MRM mode as the [M-H]- parent and 
74 m/z product at collision energy of 20 V.  Flow rate was 1 mL/min.  The right axis shows the 
gradient elution profile for % methanol.  Peak identities in (A, B) are (1) linoleoylglycine C18:2, (2) 
palmitoylglycine C16:0, (3) oleoylglycine C18:1 , (4) arichidoylglycine C20:0 and (C) are 1) 
stearidonoylglycine C18:4, (2) linoleoylglycine C18:2, (3) arachidonoylglycine C20:4, (4) 
palmitoylglycine C16:0, (5) oleoylglycine C18:1, (6) arachidoylglycine C20:0.   
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 A second elution method was developed (Figure 3-5C) using the fused-core C18 
column to determine elution of two additional analytes, arachidonoylglycine 
(C20:45,8,11,14) and stearidonoylglycine (C18: 46,9,12,15).  Although the total analysis time 
was increased 4 fold compared with the previous gradient method (Figure 3-5B); co-
elution between linoleoylglycine (C18:2) and arachidonoylglycine (C20:4) was avoided. 
 Utilizing the method developed in Figure 3-5 the ionization parameters were 
optimized to yield the lowest detection limit possible (see 3.4 Reversed Phase 
Separation of N-acyl Glycines for final parameters).  The limit of detection for each 
analyte was determined by 5 µL injection of standards between 100 nM and 10 µM.  The 
results for limit of detection (LOD = signal to noise ratio, S/N, 3) and limit of 
quantitation (LOQ = S/N 5) are shown in Table 3-1.  The calibration curves were linear 
(see Table 3-1 R2 value) between 1 – 10 µM. 
N-acyl glycine  Abbreviation LOD (µM) LOQ (µM) R2 
Stearidonoylglycine C18:46, 9, 12, 15 0.475 1.00 0.999 
Linoleoylglycine C18:29, 12 0.499 1.00 0.999 
Arachidonoylglycine C20:45, 8, 11, 14 0.484 1.00 0.999 
Palmitoylglycine C16:0 1.00 1.00 0.994 
Oleoylglycine C18:29 1.00 1.00 0.999 
arachidoylglycine C20:0 1.00 1.00 0.999 
 
 
 
 
 
 
 
Table 3-1.  LOD and LOQ for several commercially available NAGs determined by injection of 5 
µL standard solutions from 100 nM to 10 µM.  Calibration curves were linear between 1 - 10 µM.  
The LOD and LOQ were determined by a S/N of 5 and 10, respectively. 
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3.4.4 Reversed Phase Separation of Primary Fatty Acid Amides 
 Very long chain PFAMs (C12 to C22) were separated via reversed phase 
chromatography employing a sub 2 µm particle size column (Agilent RP C18 2.1 × 50 
mm, 1.8 µm particle size).  The shortest separation achieved was a 4 minute total analysis 
time (Figure 3-6). 
 
 
Due to the co-elution of oleamide, elaidamide, petroselaidamide, and 
heptadecanoamide additional gradients were developed (Figure 3-6A-D) in an effort to 
eliminate co-elution while maintaining the shortest analysis time possible.   
 
 
Figure 3-6.  Separation of very long chain PFAMs with Agilent RP C18 column (2.1 × 50 
mm, 1.8 µm particle size) using 4 different gradient separations.  Peak identities for (A-C) 
are (1) lauramide, (2) myrstamide, (3) palmitamide, (4) oleamide, (5) elaidamide, (6) 
petroselaidamide, (7) heptadecanoamide, (8) stearamide, (9) erucamide, (10) arachidamide, 
(11) behenamide. Peak identities for (D) are (1) lauramide, (2) myrstamide, (3) linoleamide, 
(4) palmitamide, (5) oleamide, (6) elaidamide, (7) petroselaidamide, (8) stearamide, (9) 
erucamide, (10) arachidamide, (11) behenamide.  The right axis depicts the gradient elution 
in % methanol. 
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 A longer gradient elution was established (Figure 3-6C), with a longer initial hold 
and slower ramp in percent methanol, to determine if petroselaidamide and 
heptadecanoamide could be resolved.  The 20 minute gradient was insufficient to 
separate the two components; additionally, further increasing the hold, ramp time, or 
temperature simply increased peak broadening with no increase in resolution (data not 
shown).  Heptadecanoamide was monitored with a separate method in future experiments 
due to the co-elution with petroselaidamide.  A final gradient (Figure 3-6D) was 
constructed in an effort to maintain the resolution of oleamide, elaidamide, and 
petroselaidamide as well as reduce the analysis time.  The final analysis time was reduced 
by approximately 2 fold and this gradient method was used in all future experiments for 
detecting PFAMs. 
 Utilizing the separation method developed in Figure 3-6D the optimized 
ionization parameters for greatest detection sensitivity were determined (see 3.5 
Reversed Phase Separation of Primary Fatty Acid Amides for final parameters).  The 
limit of detection for each analyte was determined by 2 µL injection of standards between 
500 pM and 10 µM.  The results for limit of detection (LOD = signal to noise ratio, S/N, 
3) and limit of quantitation (LOQ = S/N 5) are shown in Table 3-2.  The calibration 
curves were linear (see Table 3-2 R2 value) between 0.500 – 10 µM on average.  In cases 
where the LOD and LOQ were equal the signal was lost below the LOD, however, at this 
concentration the S/N was above 5. 
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PFAM Abbreviation LOD (nM) LOQ (nM) R2 
Lauramide C12:0 50 100 0.999 
Myristamide C14:0 50 50 0.999 
Linoleamide C18:29, 12 10 50 0.999 
Palmitamide C16:0 20 50 0.999 
Oleamide C18:19 400 400 0.999 
Elaidamide C18:19trans 40 400 0.998 
Petroselaidamide C18:16trans 40 400 0.999 
Stearamide C18:0 50 50 0.997 
Erucamide C22:113 50 100 0.998 
Arachidamide C20:0 10 50 0.999 
behenamide C22:0 20 20 0.999 
 
3.5. DISCUSSION AND CONCLUSION 
 This chapter describes various strategies for efficient separation and detection of 
saturated and unsaturated fatty acyls.  Different subclasses of lipids were resolved with a 
normal phase separation scheme utilizing a heptane and methyl-tert-butyl ether 
substituted mobile phase with gradient elution.  The addition of isopropanol to the mobile 
phase was necessary to increase the solubility of these lipids, reducing the carry over 
between injections.  Nonetheless, it was still essential to occasionally wash the column 
with polar solvents, especially if large injection volumes (> 100 µL) are used frequently.  
The fatty acyl subclasses separated via the normal phase method are those commonly 
extracted with Folch-Pi from biological samples.  This method is comparable to 
previously reported SPE methods149 and although it has an increased total analysis time 
the separation is automated and highly reproducible.  The eluent can be monitored by MS 
if a post-column feed is used or collected directly for further separation or analysis.  It 
was found that, with a 200 µL injection volume, the PFAMs and NAGs would co-elute as 
one peak between 31 and 38 minutes.  This, however, was not problematic as further 
Table 3-2.  LOD and LOQ for select PFAMs determined by injection of 2 µL standard 
solutions from 500 pM to 10 µM.  Calibration curves were linear between 0.500 - 10 µM.  
The LOD and LOQ were determined by a S/N of 5 and 10, respectively. 
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analysis conducted with MS/MS found that NAGs ionized in the negative mode while 
PFAMs were observed in positive mode. 
 Silver ion chromatographic separation of analytes with various degrees of 
unsaturation was employed to determine its viability as a technique in multidimensional 
chromatography of fatty acyls.  Argenation chromatography by TLC and GC were first 
described in the 1960’s151,152.  Later versions involving HPLC were reproduced in our 
laboratory.  In our hands it was observed that the saturated and trans-unsaturated fatty 
acid phenacyl bromides co-eluted as one peak.  Subsequently, mono-unsaturated 
components eluted, followed by di-unsaturated, and so on.  Unlike the saturated 
components, secondary separation occurred where all components with the same degrees 
of unsaturation did not co-elute.  This was attributed to the column having “uncapped” 
silinol groups causing a secondary normal phase separation.   This separation scheme was 
found to suffer from irreproducible retention times and, therefore, could not be utilized 
without a detection system.  It was unclear if the reproducibility problem was due to the 
mobile phase type146 or silver bleed, but inconsistent elution has been reported by other 
authors132. 
 Following separation of fatty acyls with either normal phase or silver ion 
chromatography the individual subclasses (eg. PFAMs or NAGs) can be further separated 
to determine the distinct analytes present.  This was achieved with C18 reversed phase 
chromatography and detected with tandem MS.   The elution order followed the trends 
observed with fatty acids eluted from reversed phase columns153.  In general, the lipids 
elute from shortest to longest acyl chain with one degree of unsaturation causing elution 
to decrease by the equivalent of 2 carbons.  For example, a C16:0 would elute at a similar 
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retention time to a C18:1.  These so called “critical pairs” were able to be separated by 
adjusting the gradient elution parameters and/or increasing the column theoretical plates.  
For PFAMs, isobaric compounds (oleamide, elaidamide, and petroselaidamide) differing 
only in double bond position were unit resolved using a 5 minute hold at 80% methanol 
followed by a 5 minute linear ramp to 100% methanol.  This resulted in LOD of 10 – 400 
nM depending on the species.  NAGs proved to be difficult to separate on standard C18 
columns due to low solubility and increased interaction with the stationary phase.  This 
often resulted in double peaks and both higher peak broadening and tailing.  Therefore, a 
C30 substituted column and a fused-core C18 column with a reduced particle size were 
employed to determine the optimum conditions for NAG separation.  Of note, in our 
hands NAGs were not found to ionize efficiently or reproducibly in positive ion mode, 
thus, negative ion mode was used for all studies. The C30 column proved useful in 
separation of saturated and monounsaturated NAGs with modest tailing, however, the 
analysis time was undesirable when considering multiple dimensional LC.  The 2.6 µm 
particle size fused-core column was expected to reduce the analysis time, broadening, and 
tailing factor.  As expected, the analysis time was reduced by 6-fold, and peaks were 
baseline resolved with minimal tailing.  Similar to observations of PFAM separation, 
NAG analysis time could not be reduced below 5 minutes and retain separation. Due to 
the low ionization efficiency of these compounds the LOD was 1 µM for all species, 
consequently, limiting the ability to detect biological levels. 
 Given the experimental limitations of silver ion chromatography, the normal 
phase chromatography method was chosen as the preferred first dimension separation 
method due to automation and high reproducibility.  An offline approach was favored as 
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The analysis time by reversed phase separation could not be reduced sufficiently which 
would lead to larger injection volumes from the first dimension.  The small column 
volume and flow rate of the second dimension would, thus, be incompatible for mixing 
nonpolar solvents of the first dimension, causing a higher background noise.  
Additionally fractionation of the NAG and PFAM peaks would lead to overall lower 
moles being analyzed per unit time and, therefore, may obscure accurate quantitation.  By 
taking time to process samples between separation dimensions all of these caveats were 
avoided.  In summary, we developed an off-line MDLC system for analysis of PFAMs 
and NAGs in vertebrate samples of complex lipid composition (see Chapter 4: Analysis 
of Swiss-Webster Mouse and Sprague-Dawley Rat Tissue via Two Dimensional 
Liquid Chromatography and Tandem Mass Spectrometry) for the highest 
quantitation integrity. 
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Chapter 4 
PFAM and NAG Detection in Tissue Samples and 
Implications for Future Studies 
 
 
4.1. ABSTRACT 
 Primary fatty acid amides (PFAMs) and N-acyl glycines (NAGs) are polar lipids 
that have been shown to be bioactive in mammals and humans.  These compounds are 
hypothesized to play an important role in bioregulation of physiological processes, such 
as sleep and mood.   Likewise, aberrant metabolism of these lipids may be a diagnostic 
tool for identifying disease.   A group of PFAM and NAG standards, ranging in carbon 
chain length from 12 to 22 with various degrees of unsaturation, were separated by a 
normal phase to isolate the PFAM and NAG subclasses.  Reconstituted fractions were 
further separated using reverse phase chromatography with gradient elution by methanol 
and water.  Components were detected by MRM mode to allow for selective detection.  
The PFAMs were observed in positive mode as the [M + H]+ peak and NAGs were seen 
in negative mode as the [M – H]- ion.  Heart, liver, and brain tissue obtained from wild 
type Swiss Webster mice and Sprague-Dawley rats were analyzed via the developed 
method to determine the biological levels of the target analytes.  Samples from mice and 
rats were found to have levels of PFAMs and NAGs at the periphery of the limit of 
detection for the described method.    Other factors, such as tissue quality and use of 
inhibitors were found to have a profound effect on sample detection.  The knowledge 
gained from this study has now poised future studies to further correlate the effect of 
behavioral phenotypes on the biological levels of these bioactive lipids. 
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4.2. INTRODUCTION 
 PFAMs are polar lipids that have established physiological properties and 
neuroreceptor interaction (see Chapter 1: Metabolism, Physiology, and Analyses of 
Primary Fatty Acid Amides).  For example, exogenous application of low levels of 
oleamide to cell lines expressing 5HTR subtypes 1A, 2A, and 2C potentiated the 
receptors with maximal effects at 100 nM3-5.  Functional studies observed maximum 
potentiation of PFAMs with acyl tail length 16 to 22 with one degree of unsaturation near 
the Δ9 position forming a hairpin-like configuration3,6,10.  In addition to interaction with 
serotonin receptors PFAMs have also been shown to modulate glycine64, GABA5,10,64,66, 
and cannabinoid receptors12,13, gap junctions71, and cellular calcium signaling71,72.  
Oleamide and erucamide have been found at elevated levels in the cerebral spinal fluid of 
sleep deprived rats, cats, and in hibernating squirrels suggesting a physiological role for 
these PFAMs15,52,100,117.  Other physiological effects induced by PFAMs include water 
modulation87, food uptake18, promote angiogenesis55,56 hypolocomotion and decreased 
body temperature17,54.   
 Degradation of PFAMs is accomplished by the enzyme FAAH and the 
mechanism is well defined42-51.  Anabolic pathways have been explored exclusively in 
vitro and are still under debate.  Proposed pathways include conversion of fatty-CoA 
substrate to N-acylglycine (NAG) by cytochrome C27-29,154, BAAT31, and glycine N-acyl 
transferase32,33.  The NAG can also be formed by an N-acylethanolamine substrate being 
converted by alcohol dehydrogenase36,38.  All of the proposed anabolic pathways for 
formation of PFAMs include the NAG intermediate being converted by peptidylglycine 
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α-amidating monoxygenase (PAM)22-26,155,156 or cytochrome C.  One notable exception 
was demonstrated by Meuller et al. where the fatty-CoA was directly amidated to the 
corresponding PFAM by cytochrome C27-29,154. 
 PAM is a bifunctional enzyme primarily responsible for the amidation of 
glycinated peptides157-166.  It is this amidation action that confers biological activity to the 
otherwise inactive peptidylglycine.  Due to this reflection, NAGs are largely believed to 
be inactive intermediates in the anabolic pathway of PFAMs.  The corresponding NAG 
was found to be inactive in experiments on oleamide’s effect on gap junction 
communication, supporting this hypothesis70.  Nonetheless, Bradshaw et al. have 
investigated the distribution of NAGs in biological samples.  Skin, lung, spinal cord, 
kidney, and liver were found to have the highest concentration of select NAGs per weight 
of dry tissue91.  The approximate concentration range in these tissues was 100 – 1600 
pmol/g. 
 Some reports exist of quantitation of PFAMs in biological samples, such as in 
human luteal phase plasma2, cerebral spinal fluid of sleep deprived cats15,117,  and lung, 
kidney, liver, and brain of pig87.  However, no comprehensive reports in a single species 
are available such as those by Bradshaw and co-workers91.   A broad, quantitative screen 
of PFAM and NAG levels in biological tissues would aid in supporting proposed 
anabolic pathways and investigating the role of these molecules in behavioral 
phenotypes.  Here we present an analytical strategy for quantitation of PFAMs and NAGs 
in biological samples. 
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4.3. MATERIALS AND METHODS 
4.3.1 Chemicals 
Methanol optima grade, formic acid optima grade, ammonium acetate, hexane, 
dichloromethane, acetonitrile, and ammonium hydroxide were purchased from Fisher 
Scientific (Fair Lawn, NJ, USA).  Oxalyl chloride, oleic acid, erucic acid, petroselaidic 
acid, heptane HPLC grade, methyl-tert-butyl-ether HPLC grade, isopropanol HPLC 
grade, acetic acid, and anhydrous dichloromethane were from Sigma Aldrich (St Louis, 
MO, USA).  N, N-dimethylformamide, heptadecanoic acid, and eicosanoic acid were 
purchased from Aldrich Chemical Company (Milwaukee, WI, USA).  Lauric acid, 
myristic acid, palmitic acid, stearic acid, and docosanoic acid were purchased from Acros 
Organics (New Jersey, USA).  Elaidic acid was from MP Biomedical Inc. (Solon, OH, 
USA) and linoleamide was purchased from Enzo Life Sciences (Ann Arbor, MI, USA).  
Oleoylglycine, Linoleoylglycine, palmitoylglycine, arachidonoylglycine, and 
arachidoylglycine were purchased from Cayman Chemicals (Ann Arbor, MI, USA). 
 
4.3.2 Lipid Extraction and Normal Phase Separation 
 Tissue samples of either Swiss-Webster mice or Sprague-Dawley rat (generously 
donated by Dr. Susan Amara) were weighed while frozen and kept on ice until extraction.  
Tissue samples between 0.2 – 2.0 g were lipid extracted via a modified Folch-Pi 
method86.  Briefly, each sample was homogenized in 20 times the weight (in mL) of 2:1 
chloroform:methanol with 1 mM indomethacin additive.  Homogenized samples were 
washed with 0.88% KCl and centrifuged at 2100×g for 60 minutes at 4oC.  After 
centrifugation, the aqueous layer was discarded and the remaining extract was transferred 
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to a clean tube and dried under nitrogen.  All glassware used was vapor silinized to 
prevent lipid adhesion167 and any use of plastic was avoided due to contamination by 
lipid slip additives168.  Each extracted sample was separated via normal phase 
chromatography utilizing a YMC PVA-Sil column (4.6 × 250 mm, 5 µm particle size).  
Gradient elution is carried out starting at 95 % mobile phase A (heptane with 0.5% v/v 
methyl-tert-butyl-ether) and increasing linearly to 50% mobile phase B (methyl-tert-
butyl-ether with 10% v/v 2-propanol and 0.2% v/v acetic acid) over 40 minutes with a 
flow rate of 1 mL/minute (gradient developed by Kroniser and Johnson, unpublished).  
Fractions were collected at 8 minute intervals and the time corresponding to NAG and 
PFAM elution was collected, dried under nitrogen, and reconstituted in 100 µL of 
methanol for further separation with reversed phase chromatography. 
 
4.3.3 Reversed Phase Separation with MRM Detection of PFAMs and NAGs 
 PFAM and NAG eluent collected from the normal phase separation were further 
analyzed by reversed phase chromatography.  NAGs were separated with a Phenomenex 
C18 fused-core column (4.6 × 100 mm, 2.6 µm particle size) using a gradient elution 
starting with 70% methanol hold for 6 minutes, followed by a linear ramp to 80% over 8 
minutes and a 1 minute hold at 80%, and ending with a 5 minute linear ramp to 100%.  
Both methanol and water mobile phases were substituted with 10 mM ammonium acetate 
to aid in ionization.  The flow rate was 1 mL/minute and the injection volume was 5 µL.  
Ionization was achieved with an ESI source operated in negative mode with optimized 
parameters: fragmentor voltage 135 V, sheath gas flow 11 L/minute, nebulizer pressure 
55 psi, nozzle voltage 500 V, capillary voltage 3500 V, drying gas flow 9 L/minute, 
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drying gas temperature 275oC, and dwell time of 500 ms.  MRM detection mode was 
used to monitor the [M-H]- parent ion and 74 m/z product ion.   
 PFAMs were separated on a Zorbax RP C18 column (2.1 × 50 mm, 1.8 µm 
particle size) with a gradient elution with methanol:water starting at 80% methanol hold 
over 5 minutes, followed by a 5 minute linear ramp to 100% methanol, and a final 3 
minute hold at 100%.  The flow rate was 0.4 mL/minute, a 2 µL injection volume was 
used, and 0.3% formic acid ionization aid was added to both mobile phases.  PFAMs 
were detected using an Agilent 6460 Triple Quadrupole Mass Spectrometer equipped 
with an APCI source.   Optimized detection parameters are as follows:  gas temperature 
325oC, vaporization temperature 325oC, gas flow 4 L/minute, nebulizer pressure 22 psi, 
capillary voltage 3500 V, corona 4 µA, fragmentor 125 V, and dwell time 50 ms.  MRM 
detection was employed to monitor elution of the [M+H]+ parent ions and either product 
ion 43 m/z for saturated components, or 55 m/z for unsaturated species. 
 
4.4. RESULTS 
 Swiss-Webster mouse and Sprague-Dawley rat tissue was analyzed according to 
quantity and availability, therefore, not all samples shown are from the same species nor 
tissue type.  Early attempts at extraction and analysis of PFAMs and NAGs from mouse 
brain suffered from contamination, obscuring identification even upon blank subtraction 
(Figure 4-1A).  This contamination was found to be leaching from micropipette tips 
during minor sample transfer steps in the Folch-Pi extraction steps.  When all sample 
contact with plastics was eliminated the contamination profile previously observed was 
attenuated and sample peaks due to tissue extractions were evident (Figure 4-1B).  
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Homogenization in SDS prior to Folch extraction was deemed unsuccessful since no 
analytes were detected from the blank or tissue sample (Figure 4-1C).  FAAH inhibitor, 
indomethacin, was employed to prevent potential degradation (Figure 4-1D).  This 
method of extraction showed the most promising results, with blank response near 
baseline levels and detection of analytes in the tissue sample.  1 µM indomethacin was 
included in all future extractions. 
 
 
Rat hearts between 1.2 and 1.4 g were analyzed for the presence of PFAMs and NAGs 
(Figure 4-2).  Three samples analyzed in the same week had very similar 
chromatographic profiles but the same PFAMs were not present in all samples (Figure 4-
2A, B, and C).    Two additional samples of rat heart were analyzed one week later with 
very different chromatographic profiles and nearly no PFAMs detected (Figure 4-2D and 
Figure 4-1.  Analysis of contamination and use of inhibitors in tissue extracts.  (A) Blank 
extract using extraction solvents with no tissue present (B) Extraction of mouse brain 
(black) overlayed with blank extract (red) excluding the use of plastic pipet tips in sample 
preparation. (C) Mouse brain extract (black) versus blank extract (red) using SDS for 
homogenization and all glass preparation. (D)Mouse brain extract (black) and blank 
extract (red) by all glass Folch-Pi extraction with 1 µM indomethacin. All 
chromatograms shown are analyzed by the reversed phase PFAM method 
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E).  Attempts to quantify the PFAMs observed in the heart samples gave a wide variation 
of concentration ranges (~300 nM to 7 µM), while some were below the LOQ.   
 
 
Mouse brain was tested because of the known interaction of oleamide with 5HTR. The 
equivalent of 10 mouse brains (3.7206 g) was analyzed to ensure adequate sample size 
(Figure 4-2F).  All PFAMs identified in the sample were below the LOQ.  No NAGs 
were detected in any of the samples. 
Figure 4-2.  Analysis of (A-E) individual Sprague-Dawley rat hearts, and (F) Swiss-Webster 
mouse brain with mid-brain removed.  Peak labels show identified PFAMs using the C:XY 
representation where C shows the acyl chain length, X is the degree of unsaturation, and Y is the 
position of unsaturation.  All unsaturation points are in the cis configuration unless otherwise 
noted. 
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Additional sample analysis displayed irreproducible chromatography, thus, the extraction 
efficiency was tested over a 3 week period with approximately 1 g of rat heart per sample 
(Figure 3).  The first week extraction, following normal protocol, had a percent recovery 
for an internal standard of 64% for the blank and 73% for the sample Figure 4-3A).  The 
baseline showed a higher variability in dynamic MRM mode for this sample, 
consequently MRM mode was used in future analysis.  Rat hearts for week 2 and 3 
extraction experiments were homogenized and kept at 4 oC until analysis. 
 
 
Week 2 samples had a percent recovery of 52% for the blank and 49% for the sample 
(Figure 4-3B).  Week 3 samples were 43% recovery in the blank and the internal standard 
in the sample solution was not detected (Figure 4-3C).   
Figure 4-3.  Time dependent extraction of individual Sprague-Dawley rat heart samples extracted 
(A) the same week of homogenization, (B) one week after homogenization, and (C) 2 weeks after 
homogenization. All samples were homogenized in 2:1 chloroform:methanol with 1 mM 
indomethacin present.  (B) and (C) were stored at 4 oC until analysis.  Data for (A) was obtained 
using dynamic MRM mode while (B )and (C) were collected with MRM mode. 
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Reproducibility issues continued after extraction efficiency studies.  After normal phase 
column regeneration protocols were conducted, rat liver was analyzed (Figure 4-4).  
While each sample had similar chromatographic profiles, no PFAMs or NAGs were 
detected.  All additional tissue analysis for rat brain, liver, and heart displayed no 
measurable amount of PFAMs nor NAGs. 
 
 
4.5. DISCUSSION AND CONCLUSION 
 Brain, liver, and heart of Swiss-Webster mice and Sprague-Dawley rats were 
analyzed for content of PFAMs and NAGs using an off-line normal phase and reversed 
phase HPLC-MS/MS method.  Initial sample extracts of mouse brain showed a high level 
of contamination evident in both the sample and the blank.  This contaminant was found 
to be extractable lipids in plastic pipette tips (Figure 1A, B).  When any tissue sample 
was extracted and prepared using only glassware, and micropipette transfer steps were 
eliminated, the blank and sample exhibited very different chromatographic profiles.  The 
addition of an FAAH inhibitor, indomethacin (IC50 = 100 µM)
43, was used to prevent 
Figure 4-4.  Analysis of Sprague-Dawley rat liver.  Each figure (A-D) represents one replicate of 
approximately 2 grams per sample.  The peaks present to not match the retention time nor m/z for 
any known PFAM determined with Agilent Mass Hunter Qualitative Analysis software. 
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enzymatic degradation of the PFAMs and NAGs present.  Addition of 1 mM inhibitor 
acted to increase the sample signal compared to the blank (Figure 1C, D).   
 After contamination and inhibitor studies were complete samples were analyzed 
for identity and quantity of select PFAMs and NAGs.  Some preliminary rat heart 
samples appeared to have comparable chromatographic profiles, possibly indicating 
similar composition (Figure 2A-E).  Future extractions of rat heart failed to reproduce the 
results obtained in Figure 2A-C.  In addition, the quantity and identity of PFAMs 
observed varied greatly between samples.    Attempts to quantitate the observed PFAMs 
yielded results ranging from 300 nM to over 7 µM, which could not be reconciled by 
examining differences in % recovery between samples.   
 The extraction procedure was tested to determine if a longer extraction time could 
increase the incidence of PFAMs or NAGs observed (Figure 3).  None of the spectra 
from week 1 to week 3 of extraction had any identifiable PFAMs or NAGs.  Because the 
signal intensities could not be directly compared the % recovery was used as a qualitative 
measure of extraction efficiency.  From week 1 to 3 the % recovery in both the sample 
and the blank decreased.  Reduction in the incidence of heptadecanoamide could be due 
to a number of factors, including minimal enzymatic degradation or oxidative damage.  
Therefore, future samples were homogenized, extracted, and dried down within 24 hours.    
Over several months of sample preparation the internal standard was increasingly 
not detected.  This issue was resolved by normal phase column regeneration, which 
removed column build-up.  The regeneration procedure was employed after 
approximately 1 mL of sample extract was injected, or every 5-7 samples.  After column 
cleaning, analysis of rat liver was conducted (Figure 4A-D).  Each sample appeared to 
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exhibit similar chromatographs, however, no PFAMs or NAGs were identified.  Indeed, 
all subsequent analyses of brain, heart, or liver contained no measurable PFAMs or 
NAGs.   
Other authors have reported finding 0.1-5 pmol/100 µL (approximately 50 nM) 
oleamide in cerebral spinal fluid15,117, and erucamide in pig lung, kidney, liver, and brain 
between 0.5 and 12 ng/g ( intermediate value of 200 nM )87.  These values fall just below 
the LOQ and LOD for oleamide determined in our optimized system.  With respect to 
other PFAMs, the LOD range is from 10 – 400 nM.  Thus, a minimum of 4 g of tissue 
must be extracted to reach the LOQ for oleamide assuming 60% recovery.  Separation of 
4 g of tissue extract by the normal phase chromatography method developed will require 
4 separate injections (approximately 11 hours) for a single tissue sample replicate due to 
sample viscosity.  Additionally, large sample sizes tended to exhibit a white cloudy film 
after reconstitution in methanol prior to reversed phase analysis.  This film was only 
transparent when dissolved with 2:1 chloroform:methanol.  Unfortunately, this solvent 
caused jamming and clogging of the auto-injection system.  One other factor that 
hindered quantitation was the system LOD and LOQ.  The system was optimized, 
however, there was little difference between many of the LOD and LOQ suggesting that 
ion transmission dropped off rapidly.   
 In conclusion, the development of a MDLC-MS/MS method allowed for the 
analysis of vertebrate tissue samples.  The incorporation of an internal standard to the 
extract aided in the validation of correct fraction collection from the 1st dimension and 
allowed for stability comparison between samples.  From these analyses several 
important factors in quantitation of PFAMs and NAGs in these samples was determined.  
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The use of plastics was found to contribute contaminants to the extract and, thus, the use 
of glass in the preparation was advantageous in reducing background.  The addition of 
inhibitors to prevent degradation of PFAMs by FAAH was found to increase the 
detection of components in the extract.  Additional factors in ensuring reliable 
quantitation, such as tissue quality and data analysis considerations, are discussed in the 
following section. 
 
4.6.  PROJECT OUTLOOK AND CONCLUDING REMARKS 
 It is clear, even with careful method selection and sample processing 
consideration, that quantitation of trace levels of the PFAM and NAG subclasses propose 
a challenge for conventional separation and detection methods.  Several factors were 
found to have a profound impact on analysis and additional experimental methodology 
should be further contemplated.  One factor found to influence detection was the use of 
tandem mass spectrometry.  Many of the PFAMs and NAGs investigated for 
determination of LOD and LOQ revealed a steep loss of signal.  For NAGs this was 
observed at 1 µM and for PFAMs it was variable between 100-400 nM (see Chapter 3: 
Chromatographic Separation Methods for Fatty Acyls).  A similar signal drop-off for 
PFAMs is observed in GC-MS with electron ionization (Davic, A. P., personal 
communication) and, thus, the LOD seems to be an inherent limitation of these analytes 
versus quality of MS instrumentation available.  This MS LOD may only be capable of 
being improved for instrumentation with ion trapping capabilities.   
 Other experimental parameters of consideration are quality and tissue and 
extraction conditions.  Tissue should be excised immediately after sacrifice and flash 
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frozen in liquid nitrogen within minutes to prevent chemical alteration.  If the excised, 
frozen sample is not processed immediately it should be stored frozen at -80oC.  Between 
removal and usage that sample should not be allowed to thaw until extraction is 
complete.  In addition, the homogenization procedure should be carried out in ice-cold 
extraction solvents to limit enzymatic hydrolysis.  The addition of indomethacin to the 
2:1 chlorofrom/methanol solvent was found to have a positive effect on detection of 
components in extracted tissue samples.  This molecule, while shown effective in 
reducing FAAH activity, is not an FAAH specific inhibitor, but affects degradation via 
the COX-2 pathway.  A more specific inhibitor should be chosen in future studies to 
ensure hydrolysis of the analytes is not problematic.  Since the FAAH active site is a 
catalytic triad containing Ser-Ser-Lys, PMSF may be an appropriate choice and has 
documented inhibition properties on FAAH43,44,47.   
 The last major consideration of PFAM and NAG quantitation should be data 
analysis.  Endogenous PFAM concentrations have demonstrated fluctuation related to 
sleep cycle15,52,117 and many other mundane events, such as food intake18, may alter these 
lipid levels.  Therefore, it is not improbable that environmental impact will cause 
genetically identical animals to display a range of endogenous concentrations.  Given 
these experimental implications the data analysis method is of utmost importance.  In 
evaluation of disease models or behavioral phenotypes, principle component analysis is 
used to differentiate aberrant levels of biomarkers.  Likewise, this approach should be 
utilized here to determine the range of endogenous variation.  These data can then be 
compared to numerous animal models of disease and behavior to determine if any 
correlation can be ascertained.   
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 In conclusion, experimental factors, including tissue quality, extraction 
preparation, and data analysis methods will need to be altered and rigorously conducted 
to render reliable quantitation results.  MS/MS, while a highly sensitive detection 
method, was not sufficient in this study given the characteristic limitation of PFAM ion 
transmission.  Currently our laboratory is working on a new PFAM detection platform 
utilizing microdroplet derivitization and laser induced fluorescence detection.  In this 
detection system separated eluents from a chromatographic system are mixed with 
fluorescent derivitization reagents in nano-droplets formed on a microchip by 
perpendicular, fast flow of an immiscible phase.  The design of the microchip channels 
enhances mixing of the fluorescent reagents via turbulent convection.  The fluorogen tags 
in this method have no native fluorescence, a large stokes shift, and are selective for 
primary amines.   The un-optimized LOD for this system is in the attomole range (Davic, 
A. P., personal communication) compared to the above 150 femtomole LOD.   This lower 
LOD combined with the selectivity of the derivitization will enable quantitative 
measurement of PFAMs with a reduced use of tissue.  Therefore, changes in PFAM 
levels could be tested and compared to behavioral phenotype experiments to determine 
the significance of these bioactive signal lipids on physiology.   The use of fluorescent 
tagging and sub-attomole detection with microdroplet reaction and laser induced 
fluorescence platforms being undertaken in our laboratory will provide a more effective 
means of determining the endogenous trace concentrations of these bioactive lipids. 
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Appendix 1 
Palmitoylethanolamine Stability in Fluorocarbon 
Emulsions:  A Delivery System for Treatment of 
Chronic Pain 
 
 
A.1. ABSTRACT 
Palmitoylethanolamine (PEA) is an endogenous molecule that has been found in a wide 
variety of sources including plants, like peanut and soy, as well as various vertebrates.  
Although PEA does not directly interact with known cannabinoid receptors, it has 
documented cannabimimmetic effects. Treatment or ingestion of this compound is known 
to produce a myriad of potentially advantageous physiological responses, most notably 
anti-inflammatory and analgesic effects.  PEA was incorporated into nano-emulsions 
containing fluorocarbon with the intent to trace drug delivery in vivo.  A selective and 
sensitive method was developed utilizing HPLC-MS/MS with MRM detection of the [M 
+ H]+ parent ion and protonated ethanolamine product ion to determine the incorporation 
and stability of PEA in these nano-emulsions.  Detection and quantitation limits for the 
optimized method reached 1 femtomole.   
 
A.2. INTRODUCTION 
 N-acyl ethanolamines (NAEs) are congeners of fatty acids containing an 
ethanolamine moiety and are a subclass of the fatty acyl lipid group outlined by Fahy et 
al.169  This group of lipids is biosynthetically produced by cleavage of membrane N-acyl 
phosphatidylethanolamines to NAEs by a phospholipase D170-172.  Deactivation of these 
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compounds is achieved by fatty acid amide hydrolase (FAAH) and N-acylethanolamine-
hydrolyzing acid amidase (NAAA), preferential for anandamide (AEA) and 
palmitoylethanolamine (PEA), respectively (for a review see Tsuboi et al173), resulting in 
ethanolamine and the corresponding fatty acid.    While both of these enzymes degrade 
NAEs they are structurally and functionally dissimilar.  FAAH and NAAA show no 
sequence homology and FAAH hydrolyzes compounds optimally at pH 8.5-10, whereas 
NAAA is most active at pH 4.5-5.  Fluorescent tagging experiments of these degradative 
enzymes show a membrane-like distribution of FAAH and a dispersal of NAAA 
reminiscent of cytosolic or lysosome residence. 
 NAEs are endogenous compounds have been characterized in a wide range of 
species and tissues.  Of the discovered NAEs, the endocannabinoid AEA is the most 
studied.  AEA was first isolated from porcine brain and described by Devane et al.174 as 
an endogenous compound that binds to the cannabinoid receptor, most notorious for its 
interaction with the psychoactive component in cannabis.  The extensive amount of 
information available on AEA is beyond the scope of this text and will not be covered in 
detail, except in comparison to PEA (additional information on AEA is reviewed in113-
115).  
 PEA was first described in 1954 as a compound in whole egg yolk and alcohol 
soluble fractions of egg, but not in protein or acetone fractions, that was found to reduce 
mean swelling index in joints of guinea pigs and pig weanlings when challenged with 
anaphylactic arthritis175.  The structural identity of the active component in egg was not 
identified until several years later by Kuehl et al.176  Since its discovery, PEA has been 
identified in a wide variety of plant and animal sources, including peanut oil and soy 
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lechtin177, sea urchin ovaries178, central nervous system of leech179, several species of 
bivalve molluscs180, pig181, cow181, sheep181, mouse182, rat183,184, and human121.  
Concentrations of NAEs in these tissues are reported in the pmol/g range. 
 The most notable physiological properties of PEA identified to date are its 
propensity for anti-inflammatory and analgesic effects.  In models of neuropathic pain 
induced by chronic constriction injury treatment with subcutaneous injections of 
30 mg/kg PEA attenuated pain response from noxious and non-noxious stimuli in wild 
type mice185.  Additionally, PEA administration prevented changes in number of fibers, 
myelin thickness, axon diameter, and reduced 50% of edema in nerve fibers.  Injections 
of PEA over a 14 day period also reduced the number of inflammatory infiltrate cells 
observed at the injury site.  These anti-inflammatory and protective effects were not 
observed in PPARα null mice.  LoVerme and coworkers found similar results for PEA 
treatment in chronic constriction injury model of neuropathic pain186.  They also 
described a diminished nociceptive behavioral response to formalin, magnesium sulfate, 
and carreegnan induced hyperalgesia.  Reduction of edema was not evident until 1 h post 
injection, although analgesic effects were evident shortly after treatment.  Attenuated 
pain response was abolished by CB2 antagonist, SR144528, and inhibitors of calcium 
mediated potassium channels.  CB2 knock-out mice were still responsive to anti-
inflammatory and analgesic effects of PEA; providing evidence that PEA is not an 
endogenous ligand for CB2 receptors, but exerts cannabimimetic properties. Paw 
withdraw latencies of mice administered a single dose of PEA versus those treated with 
the drug for 7-14 days showed similar results, both of which were higher than mice 
receiving vehicle, suggesting that PEA does not prompt a developed tolerance over the 
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time period tested.  In line with previous reports, formalin and carrageenan induced 
edema and hyperalgesia were reduced with PEA treatment187.  PEA was also shown to 
diminish the number of mast cells present, as well as plasma extravasation caused by 
substance P.  Mast cells were previously shown to be down modulated by exogenous 
PEA application188.  These effects were revealed to be dose-dependent.  Injection of 
palmitic acid and ethanolamine were ineffective, proving PEA, and not its metabolites, 
elicited the observed response187.  Interestingly, PEA and AEA co-administered in 
formalin induced pain models were found to be 100 fold more potent than either 
compound alone189.  These synergistic effects between PEA and AEA were also 
demonstrated by enhanced relaxation of rat mesenteric arteries78.  Attenuated response to 
pain by AEA and PEA were even more potent when delivered locally, rather than 
systemically189.  Observed analgesia was reversed by CB2 antagonist SR144528; CB1 
antagonist and opioid antagonist, naloxone and SR141716A, were ineffective.  
Additionally, a selective inhibitor of the main degradative enzyme of PEA, NAAA, was 
shown to have similar effects as PEA administration in a carrageenan pain and 
inflammation model190.  Inhibitors of FAAH, the main catabolic enzyme of AEA, had no 
effect.  This data suggests that, while some effects of endogenous NAEs may be ascribed 
to the so called “entourage effect” (a hypothesis that endogenous NAE properties are due 
to the increased half-life of AEA), these lipids clearly have their own properties distinct 
from AEA.    PEA treatment has been reported to reduce lipopolysaccharide-induced 
nitric oxide production in RAW264.7 macrophages191.  Thus the analgesic and anti-
inflammatory properties of PEA may be attributable to attenuation of nitric oxide 
production, which is a known pro-inflammatory.  
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 Curiously, other reports of inflammation models and various disease states have 
shown an endogenous modulation in PEA and other congeners.  Intraperitoneal injections 
of cadmium chloride in Wistar rat testes exhibited a drastic increase in PEA, 
stearoylethanolamide (SEA), and AEA that was time-dependent with total NAE levels 25 
fold higher at 9 h post injection183.  In patients with osteoarthritis and rheumatoid 
arthritis, diseases that involve pain and inflammation of the joints, levels of PEA, and to a 
lesser extent OEA, were found to be dramatically reduced compared to control groups192.  
Examination of the CSF of patients with schizophrenia found the PEA and AEA were 2 
fold higher versus control groups121.  Tests of stress and anxiety found PEA and OEA 
concentrations in the serum increased when patients were exposed to a stressful 
situation122.  Additionally, in patients characterized as having chronic wide spread pain 
and chronic neck and shoulder pain that, generally, pain score intensities correlated 
negatively with PEA and SEA levels120.   It is unclear in the disease states presented here 
if aberrant levels of NAEs are due to metabolic defects or are modulated as a down-
stream response.  
There is some evidence that indicates elevated levels of PEA and other NAEs act 
in a protective manner.  PEA, SEA, oleoylethanolamine (OEA), and 
linoleoylethanolamine were found to increase in infarcted canine myocardium193.  It is 
also known that PEA accumulates in ischemic tissues and protects cerebellar granule 
cells against glutamate excitotoxity194.  Addition of AEA was found to antagonize the 
protective effects of PEA in glutamate excitotoxicity. Exogenous application of PEA (1 – 
1000 nM) reduced the number of microglial cells and protected dentate gyrus granule 
cells in excitotoxically lesioned hippocampal slice cultures.  These effects were abolished 
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by PPARα, but not PPARγ, antagonists195.  In models of ischemia, administration of 10 
mg/kg PEA to rats, either 30 min before or during middle cerebral artery occlusion, 
significantly reduced the infarct volume and neurological deficit score196.  Several 
proteins found to be up regulated in ischemia had reduced levels in animals receiving 
PEA pretreatment.  Rats which were given AM404, an NAE uptake inhibitor, were found 
to have larger infarct volumes and higher neurological deficit scores.   Again, PEA and 
AEA levels were enhanced in the spinal cord of mice in an animal model of multiple 
sclerosis182.  Intravenous injections of PEA and AEA improved spasticity within 10-30 
minutes.  PEA was found to dose-dependently reduce impairment, normalize learning 
profiles and working memory in an animal model of Alzheimer’s disease197.  As with the 
anti-inflammatory and analgesic effects mentioned previously, learning and memory 
benefits associated with PEA treatment were absent in PPARα null mice.  Finally, 
intraperitoneal injections of PEA (EC50 8.9 mg/kg) in maximal electroshock seizure tests 
were found to have an anticonvulsive property198.  In chemical induced seizures, PEA 
was only effective against tonic convulsions of pentylenetetrazol and 3-
mercaptropropionic acid.  Overall, PEA reduced lethality associated with convulsions. 
NAEs exert other cannabimimmetic effects, such as alteration of food uptake.  
Guinea pigs and rats deprived of food for 12-18 h had elevated levels of PEA in the brain 
and liver199.  In contrast to AEA18, SEA, PEA, and OEA intraperitoneal injection were 
found to decrease food intake in starved rats200 and mice201.  Food deprivation acted to 
reduce the biosynthesis of OEA200.  The anorexic effect of OEA was not affected by CB1 
or CB2 antagonists, SR141716A and SR144528, respectively.  Intracerebroventricular 
injection did not cause a decrease in food consumption, indicating that the anorexic 
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effects are not mediated by the central nervous system200.  Reduction in food 
consumption invoked by treatment with SEA (up to 100 mg/kg) was not accompanied by 
sedation, illness, or diminished motility and body temperature.  No other changes in 
glucose, triglycerides, or cholesterol levels were apparent.  Administration of stearic acid 
did not alter food consumption versus controls.  Interestingly, OEA and PEA were found 
to increase in the white adipose tissue of Wistar rats exposed to 4oC for up to 6 h202.  
Elevation in NAEs was accompanied by increases in N-acyl transferase, but not FAAH.  
Exposure of adipocytes to noradrenaline and isoproterenol, beta-adrenergic agonists, 
elevated levels of OEA and PEA in cells while, the beta-adrenergic antagonist, pranolol, 
blocked the increases.   
Due to the prevalence of these molecules in biological systems and the discovery 
of multiple orphan G protein coupled receptors, NAE binding has been investigated in 
orphan GPR55 and GPR119 receptors.  Sequencing of GPR55 revealed that rat and 
mouse shared 75 and 78% identity, respectively, with human203.  GPR55 shares relatively 
low sequence identity with CB1 and CB2 receptors, 13.5% and 14.4%, respectively204.  
mRNA levels were highest in the gastrointestinal tract, adrenal gland, central nervous 
system203, and large dorsal root ganglion neurons204.  Expression of GPR55 in HEK293 
cells discovered that AEA, OEA, and PEA were able to bind with EC50 values of 18, 440, 
and 4 nM via radiolabeled binding assays with GTPγS.  Surprisingly, THC was able to 
bind at an EC50 of 8 nM, which is of higher affinity than its binding with CB1 or CB2 
receptors, suggesting this orphan receptor may be a newly discovered cannabinoid 
receptor203,205.  Exogenous application of AEA and THC to HEK293 cells expressing 
GPR55 acted to increase intracellular calcium and reversibly suppress M type potassium 
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currents204.  PEA had no effect on calcium release.  GPR119 is expressed mainly in the 
gastrointestinal tract, pancreas, and brain206.  AEA, SEA, OEA, and PEA were shown to 
activate human and mouse GPR119 in a yeast fluorescence assay, with OEA being the 
most potent.  Due to this orphan receptors’ localization in the gastrointestinal tract and its 
affinity for OEA, this receptor-ligand interaction was hypothesized to mediate the 
anorexic effects observed with OEA treatment and indeed synthetic, selective agonists of 
GPR119 produced a hypophagic effect. 
 Here we present method development and analysis of PEA stability in 
fluorocarbon nanoemulsions by HPLC-MS/MS.  Fluorocarbon nanoemulsions have been 
previously demonstrated as drug delivery vehicles for poorly soluble drugs, such as the 
anti-inflammatory, celecoxib207-209.  Following this rationale, PEA formulation into 
fluorocarbon nanoemulsions was undertaken.  Here we present development of a 
sensitive analytical methodology to track incorporation and stability of PEA in new 
fluorocarbon nanoemulsion formulations. These studies were undertaken in light of the 
vast evidence for PEA as an analgesic with the intent to deliver and potentially track drug 
distribution in vivo in preclinical models of chronic pain.  Tracking drug distribution will 
aid in determining how much of the drug reaches inflammation sites and how quickly it is 
degraded in vivo. 
  
 
 
A.3. MATERIALS AND METHODS 
A.3.1 Chemicals 
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Methanol, optima grade, chloroform, HPLC grade, and formic acid, optima grade 
were purchased from Fisher Scientific (Fair Lawn, NJ, USA).  Palmitoylethanolamine 
was purchased from Tocris Bioscience (Bristol, UK).  Fluorocarbon nano-emulsions were 
kindly provided by Dr. J. Janjic (Department of Pharmacy, Duquesne University, 
Pittsburgh, PA) 
A.3.2 Methods 
 PEA extracts were crudely separated on a Zorbax RP C18 column (2.1 × 50 mm, 
1.8 µm particle size) with isocratic elution of 80:20 methanol:water containing 0.3% 
formic acid as an ionization aid.  The flow rate was 0.4 mL/minute, a 2 µL injection 
volume was used, and the eluent was detected using an Agilent 6460 Triple Quadrupole 
Mass Spectrometer equipped with an ESI source.   Optimized detection parameters are as 
follows:  gas temperature 275oC, sheath gas temperature 300oC, gas flow 5 L/minute, 
sheath gas flow 11 L/h, nebulizer pressure 45 psi, capillary voltage 4000 V, nozzle 
voltage 450 V, fragmentor 135 V, and dwell time 200 ms.  MRM detection was 
employed to monitor elution of the [M+H]+ parent ion at 300 m/z and product ion 62 m/z 
at a collision energy of 20 V. 
 
A.4. RESULTS 
PEA was directly infused using at Harvard Apparatus syringe pump at a flow of 0.2 
mL/min in a 6460 Agilent Triple Quadrupole to determine the compound ionization and 
optimum collision energy (Figure A-1A).  A crude separation method was developed to 
reduce ion suppression effects and determine the most sensitive ESI ionization 
parameters and MRM detection (final method described in Section 3.2 Methods).  The 
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CID patterns were found to consist of [M+H]+ parent ion, the loss of a hydroxyl group to 
yield the product ion 283 m/z, and fragmentation of the head group giving a protonated 
ethanolamine moiety at 62 m/z (Figure A-1B).  The linear range was found to be 500 pM 
- 80 nM and the LOD and LOQ were equivalent at 1 femtomole (Figure A-2). 
 
 
 
 
 
 
 
Figure A-1. (A) CID of 1 µM PEA directly infused using a Harvard Apparatus 
syringe pump connected to a 6460 Agilent Triple Quadrupole MS equipped 
with ESI operated in positive mode.  (B) Proposed fragmentation of PEA 
showing loss of a hydroxyl at 283 m/z and a protonated ethanolamine at 62 m/z.   
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Nano-emulsions were freeze-thawed, extracted with a solution of 2:1 
chloroform/methanol (HPLC grade), and an aliquot of the organic phase diluted in 
methanol to give an expected final concentration within the linear range.  As in earlier 
work, the use of plastic was avoided in the sample preparation process due to use of 
extractable lipids in the plastic manufacturing process168.  Early formulations of the nano-
emulsions contained olive oil to aid in the solubilization of lipophilic PEA, therefore a 
control sample was prepared with equivalent concentrations of olive oil to determine the 
possible interferences.  The presence of olive oil exerted no negative effects on PEA 
detection evidenced by matching expected and measured values (Table A-1).  Regardless, 
emulsions Emulsion 1 and 2 contained approximately 10 fold lower detected 
concentrations than those expected.  Further avenues were explored, such as 
Figure A-2.  (A) Concentrations of PEA from 500 pM to 80 nM were used to 
determine the linear range with isocratic elution in 80:20 methanol/water and an 
ESI ionization and MRM detection on a 6460 Agilent Triple Quadrupole using 
the parent ion 300 m/z  and product ion 62 m/z.  (B) The expanded calibration 
curve from 500 pM to 7 nM to show linearity in the lower range. 
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measurement of PEA in the supernatant versus the pellet of freeze-thawed samples, 
increasing the concentration of the final sample from 50 to 500 nM (Table A-1), and 
addition of a normal phase pre-separation step (data not shown).  Pre-separation of 
emulsions compared with a control sample did not increase levels of detection. Addition 
of ethanol to emulsions Emulsion 3 and 3F (5F is a microfiltered sample identical to 
Emulsion 3) greatly improved the ability to detect PEA, although, the microfiltered 
sample showed an almost 2 fold lower than expected value.  Ethanol was added only to 
aid in solubility of the drug into a surfactant mixture and was evaporated from the final 
sample prior to testing. The same Emulsion 3 and 3F samples were tested again one week 
post preparation and PEA levels were found to decrease significantly.  Lower levels of 
PEA after one week suggested degradation of PEA in the emulsion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample Expected (nM) Measured (nM) 
Control  75 72 ± 2 
Emulsion 1 500 58 ± 1 
Emulsion 2 500 59 ± 1 
Emulsion 1 
Supernatant 
Pellet 
 
50 
0 
 
4 ± 2 
5 ± 2 
Emulsion 2 
Supernatant 
Pellet 
 
50 
0 
 
5 ± 2 
3 ± 2 
Emulsion 3 50 45 ± 1 
Emulsion 3F 50 29 ± 1 
Emulsion 3 – 
1 week post preparation  
50 21 ± 2 
Emulsion 3F – 
1 week post preparation  
50 8 ± 2 
Table A-1.  Quantitation of PEA in nano-emulsions.  The control sample contained 
concentrations of PEA and olive oil equivalent to those present in the prepared 
emulsions.  The expected concentration values are those of the final sample after dilution 
for HPLC-MS/MS.  F indicates samples which were filtered after preparation.  Measured 
values show those obtained by peak integration and interpolation from the prepared 
calibration curved.  Statistical values were obtained using the formula for standard error 
in the least squares fit. 
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A.5. DISCUSSION AND CONCLUSION 
We have successfully determined parameters of a sensitive detection method for 
PEA.  The linear range of 500 pM - 80 nM was chosen due to the high linearity of fit 
which were greater than 0.9995 (R2). The LOQ and LOD for PEA with this method was 1 
femtomole (500 pM), which is equivalent to those being currently reported for detection 
of NAEs210-212.  Analysis of fragments generated by CID identified a quantitative product 
ion at 62 m/z matching the mass of a protonated ethanolamine ion.  This finding indicates 
that NAEs can be sensitively and selectively analyzed as the ethanolamine moiety gives a 
unique point of identification over other lipid classes that frequently yield indistinct acyl 
fragments.  Analysis of nano-emulsions by this method proved challenging as the 
measured concentration was always less than expected based on the amount of PEA 
added to initial samples.  This could be explained by the strong surfactants used in the 
dissolution of PEA in the aqueous based solution, since critical micelle index may not 
have been sufficiently exceeded, thus, impeding the extraction process. Another factor 
obscuring detection of PEA in nano-emulsions could be the storage or preparation 
processes.  Chemical information available on PEA indicates that this material is light 
sensitive and therefore stocks or emulsions left in contact with light may have degraded.  
This may explain the decrease in PEA detection observed of samples 1 week post 
preparation. The process of freeze-thawing the emulsion before extraction was necessary 
to remove the fluorocarbon component.  This was the layer referred to previously as the 
“pellet”.  Stock solutions of PEA prepared in a 2:1 chloroform/methanol solution and 
stored at -80oC tend to irreversibly crystallize, signifying degradation (personal 
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observation).  It is possible that repeated freeze-thawing events intended to purify the 
sample may cause degradation of the active component.   
In future analyses of nano-emulsions and animal treatment with such, several 
important factors should be considered.  Samples prepared with PEA should be stored in 
a location where light exposure is limited.  Optimum storage temperature, either room 
temperature or chilled, would need to be determined with additional stability 
experiments.  Based on previous observations, freeze-thawing of emulsions should be 
avoided to preserve the chemical integrity of the sample.  Due to the unreactive nature of 
fluorocarbons and use of a selective MRM method it is likely that the presence of this 
component will not be problematic for the detection or conservation of instrumentation 
hardware.  As surfactant micelle strength may be problematic, matrix conditions should 
be carefully selected.  Many current reports of animal treatment with PEA have employed 
a mixture of tween 80 and polyethylene glycol or PBS with a final dilution in sterile 
saline to 20:10 v/v182,185,197.  Therefore, it may be of interest to determine PEA stability in 
a common formulation currently used in in vivo experimentation.  Additional 
considerations included brand of extraction solvents, SPE column type, and treatment of 
tissue samples post-excision.  A recent report demonstrated that the brand of SPE 
column, with identical packing material, resulted in astonishingly different recoveries of 
NAEs213.  This finding carried over into the brand of chloroform used, where some 
brands resulted in chlorination of unsaturation points, thereby, obscuring true levels of 
NAEs (OEA in particular).  While PEA will not be affected by chlorination, these authors 
provide great evidence for the importance of rigorous method development.  Final 
concerns are due to post-mortem quantitation of NAEs in animal samples.  Several 
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authors have described an increase in levels of measured NAEs post-mortem in tissue 
exposed to ambient conditions180,181 and generally in necrotized tissue193,194.  Schmid et 
al. reported a linear increase in levels of PEA, OEA, SEA, and AEA with time spent at 
ambient temperature post-mortem181.  Increases were dramatic with 37, 33, and 72 fold in 
pig, sheep, and cow at 22 h ambient temperature.  This finding was corroborated by Sepe 
with substantial increases in PEA, OEA, AEA, and SEA in bivalve molluscs, but not 
boiled mollucs, at increasing time at ambient conditions180.  Therefore, excised animal 
tissue should be used immediately or quickly stored at -20oC.  Extractions should be 
carried out in the shortest time frame possible with ice cold solvents until residual matter 
can be removed.  It would also be prudent to consider the use of enzyme inhibitors for 
both biosynthesis and degradation of the desired analytes.   
In summary, PEA is a lipophilic molecule with a long history of physiological 
benefits, including anti-inflammatory and analgesic properties.  As this compound is 
endogenously produced, it appears to have few negative side effects that have been 
reported in in vivo tests to date.  It is, therefore, an attractive candidate for treatment of 
afflictions of chronic pain and inflammation.  Here we have described a method with 
sensitive and selective detection of this endogenous compound.  Current nano-emulsions 
analyzed have proved troublesome in the detection and stability of PEA.  Even though 
biosynthesis is prevalent, ex vivo preparation is complicated by its lipophilic nature.  
Nevertheless, the small considerations in sample preparation mentioned previously may 
prove invaluable in correcting stability hurdles experienced thus far.  Additionally, oral 
dosage, though less effective, has proven successful.  Tracking of drug delivery in a solid 
form may be accomplished with enriched radiolabeled PEA.  While small scale 
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experimentation would be initially expensive; this would not be necessary to carry into 
clinical settings.  Therefore, PEA proves to be a viable treatment strategy with an 
optimistic future for alleviating individuals afflicted with chronic pain. 
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